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ABSTRACT:
More than 300 million biospecimens – blood samples, saliva swabs, excised tumors – are 
housed in different collections all over the country right now. Meanwhile, biometric data is 
constantly being compiled by sophisticated security systems, by lifestyle products, and even 
by ordinary ATMs. Because private companies, hospitals, for-profit testing facilities, and 
security companies ‘own’ the information they collect, it can’t work for you.
Billions of dollars in grants are spent each year on focused medical studies seeking infor-
mation that is most likely already available, but unobtainable. The availability of biometric 
information to researchers able to draw real statistical conclusions from it is impeded both 
by a shaky notion of individuals’ privacy and the proprietary funding structure by which much 
of the information has been gathered.
The data is out there – it’s not a question of wanting to share personal data or not. 
Measures like the Genetic Information Nondiscrimination Act treat a symptom of the end of 
privacy, but by no means secure it.
The only productive embrace of this national mine of information is to make it fully transpar-
ent, to make it available to the public and researchers alike, to nationally acknowledge the 
end of an antiquated notion of privacy, and to stave off the flow of research dollars into 
patented pharmaceuticals. The Biobank for America does just that by making transparent the 
collection and storage of biometric information on a national scale and finally collating it into 
a comprehensive, searchable archive. 
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9This book is at once a proposal - a thesis 
proposing a solution to a problem - and a 
commentary on the process, a director’s 
cut of the project. My research began in 
February of 2010, when I knew that I was 
interested in archives, in huge national in-
stitutional structures, and I was definitely 
not interested in the public, or what I saw 
as public space in architectural design. An 
archive, I thought, would be inaccessible, 
mute, filled with silent artifacts, and easy 
to deal with. 
What became clear in the months that fol-
lowed is that this archive is a fundamen-
tally public problem, a reaction to archaic 
entrenched biomedical research structures. 
Rather than drawing a boundary around my 
project, keeping the public out and arti-
facts in, I found a new way of conceiving 
of the public, at least for me. For the first 
time in my projects, the program did not 
just include a wish for transparency, a de-
sire that the public might enjoy a view into 
the work of a research institution - it was 
imperative. What is different in my project 
from any biotech building you might find in 
Cambridge is that it actively attempts to 
build a relationship between the material 
stored and operated on, and the public - 
the source of the stored material. 
While it may position my work as more 
tentative, as less assured or confident, 
to include the many branches of my inves-
tigation, of my research, I am well aware 
that I am no longer selling this project. It 
has been presented, it has been discussed, 
and I am packaging it for archiving only 
a few weeks later. What I believe is the 
most compelling, or perhaps just useful to 
future readers (who I can only imagine to 
be students in Thesis Prep preparing their 
FOREWORD
own topics of research), is how ‘Biobank’ 
changed from a crazy conversation with my 
father about Austin Powers-style cryonic 
storage into something I really believe in. 
I believe America needs a Biobank, I believe 
America needs a comprehensive overhaul of 
its biomedical research structure, and I be-
lieve that someone working in architecture 
can acquire enough knowledge on the topic 
to arrive at meaningful conclusions. 
In the spirit embraced by the fiction of 
this project, I include dead ends, sketches, 
ephemera from the process in acknowledg-
ment that I don’t know, I can’t know, what 
is useful here. It is of course curated, I 
can’t help that, but there is an intentional 
over-share going on here, an exposure of 
my own thinking. The library won’t break 
by virtue of these extra pages, these few 
additional megabytes. In some sense, this 
sort of inundation devalues each individual 
piece, and that’s the point. 
In just the same way that the quantity of 
personal information available in the Bio-
bank I propose protects individuals, this 
spewing of reflections, ideas, and research 
leaves it up to the reader to form conclu-
sions, to draw out meaningful connections, 
and to pick up where I left off. 
This is an archive of excess. This is the 
Biobank for America. 
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MIT gave me a grant for $125 to “get my 
genome sequenced,” which is what this company 
promised me. This is what I got in the mail. 
Apparently my DNA knows that I am a “single 
female individual.” Huh. 
1920 1930 1940 1950 1960 1970 1980 1990 2000 2010
1915:
Richard Lewisohn at Mount 
Sinai Hospital in New York 
City developed the use of 
sodium citrate as an 
anticoagulant, allowing blood 
to be stored outside the 
body for later transfusion.
1915:
Richard Weil demonstrated 
the refrigerability of 
anticoagulated blood, 
allowing it to be preserved 
for long periods of time.
1917:
During World War I, Oswald Hope 
Robertson, a US ARMY officer 
established a “blood depot” in 
Britain. He is recognized as the 
creator of the first blood bank.
1930:
The Soviet Union 
established 60 large blood 
centers with nearly 500 
smaller subsidiaries for the 
storing and shipping of 
“canned blood.”
1937:
Bernard Fantus, at the Cook County 
Hospital in Chicago started the first 
“blood bank,” leading to the 
establishment of similar facilities in 
hospitals across the United States.
1940:
Willem Johan Kolff opened the first 
blood bank in Europe.
1943:
JF Loutit and Patrick L. Mollison 
introduced acid-citrate-dextrose 
(ACD) solution, which improved 
anticoagulation and storage time for 
blood samples.
1950:
The plastic bag was introduced by Carl 
Walter and WP Murphy as a replacement 
for glass bottles, improving the efficiency 
of blood collection and safety during 
storage. Separation of blood components 
is also promoted by this move. 
1979:
CPDA-1, a new anticoagulant 
preservative was introduced. This 
decreased wastage and facilitated 
resource sharing between blood 
banks.
1939:
Karl Landsteiner, Alex Wiener, Philip 
Levine, and R.E. Stetson discovered 
the Rh blood group, which was 
previously cause of the majority of 
transfusion reactions.
1944:
Avery, McLeod and McCarty 
demonstrate DNA is the hereditary 
material.
1953:
WATSON AND CRICK 
describe the double helical 
structure of DNA.
1972:
Cohen and Boyer develop 
recombinant DNA 
technology.
1974:
Issuing of Belmont Report on use 
of human subjects in research.
1983:
First human disease gene mapped 
with DNA markers - Huntington’s 
Disease.
1984:
First public discussion of 
sequencing the human genome.
1986:
Muscular dystrophy gene identified 
by positional cloning.
1988:
Human Genome Organization (HUGO) 
formed.
1989:
Cystic fibrosis gene 
identified by positional 
cloning.
1990:
Human Genome Project (HGP) 
launched in the US. 
First gene for breast cancer 
(BRCA1) mapped.
1992:
Second-generation 
human genetic map 
developed.
1998:
Incorporation of 30,000 genes into 
human genome map.
Chinese National Human Genome 
Centers (in Beijing and Shanghai) 
established.
1998:
Iceland’s Bill on a Health Sector 
Database passed (HSD)
*(Jan. 1999, fully approved Act)
JUNE 26, 2000
DRAFT OF HUMAN GENOME SEQUENCE FINISHED - 
President Clinton and Prime Minister Blair support new 
stem cell research projects.
2001:
Draft version of human 
genome sequence 
published.  
2003:
Finished version of human genome 
sequence established. 
2003:
Nearly 20,000 people opted 
out of the Icelandic Health 
Sector Database 
(statistically significant)
1999:
Full-scale human sequencing begins.
1995:
US Equal Employment Opportunity 
Commission issues policy on genetic 
discrimination in the workplace.
1996:
First human gene map established.
1978:
LOUISE BROWN, the first IVF live 
birth, born through research by 
Steptoe and Edwards, Greater 
Manchester, UK.
1973:
Transient biochemical pregnancy 
reported by Australian Foxton 
School researchers
1976:
Ectopic pregnancy reported 
by Steptoe and Edwards
1983:
The first pregnancy derived 
from a cryopreserved 
embryo reported by Alan 
Trounson and Linda Mohr
1980:
Sweden bans anonymous sperm 
donation
2010:
UK clinics forced to confirm that a 
limit of 10 children may be born 
from a single sperm donor
AUGUST 23, 2010
US District Court Judge Royce Lamberth 
reinterprets the federal ban on embryo 
destruction to encompass all research 
involving embryos.
MARCH 9, 2010
PRESIDENT OBAMA signs new stem 
cell research legislation, permitting 
greater institutional freedom. 1973: UNIFORM PARENTAGE ACT
“If a wife is artificially inseminated with donor semen 
under a physician’s supervision and her husband’s 
written consent, the husband is recognized legally as 
the natural father.”
1993:
Manhattan Family Court ruled 
against sperm donor Thomas 
Steel’s paternal rights
1990:
UK’s Human Fertilisation and 
Embryology Act - Licensing of 
clinics and protection of sperm 
donors from legal responsibility for 
their resulting biological children.
1983:
The first successful transfer of a 
fertilized egg from one human to 
another - Harbor UCLA Medical 
Center, Dr. John Buster
2009:
McD v L - Ireland Supreme Court 
ruling granting a sperm donor 
visitation rights to a child born via 
artificial insemination
1980:
First successful retrieval of sperm 
from a cadaver, from a brain-dead 
30-year-old man following a motor 
vehicle accident.
1998:
First successful conception using 
sperm retrieved post-mortem
1996:
Dolly the Sheep born : the first 
mammal to be cloned from an adult 
somatic cell using nuclear transfer. 
Because Dolly was cloned from a 
mammary gland, she was named 
after the “famously curvaceous” 
Dolly Parton
2007:
Grand Chamber of the European Court 
of Human Rights rules against Natalie 
Evans in her battle to be inseminated 
with embryos stored when she was 
married to Howard Johnston
2001:
George W Bush established federal policy restricting 
the federal funding of hESC research to research 
conducted on cell lines created before that date. 
1980:
Bayh-Doyle Act - Allows federally 
funded research institutions to 
profit from their discoveries, and 
to patent individual gene lines
1990:
California Supreme Court - Moore 
v. The Regents of the University 
of California - Plaintiff provided 
Leukemia tissue samples that were 
used to create a patented cell line 
- ended up just providing clearer 
informed consent language
2003:
Greenberg v Miami Children’s 
Hospital Research Institution - 
donors attempted to get royalties 
once a research had patented a cell 
line - they were denied
2007:
Washington University v Catalona - Prostate 
cancer research donors did not have rights to 
their samples 
1998: 
California v Greenwood - Narcotics 
ring broken up based on warrant-
less searches of trash left on the 
curb. Decision that the trash 
outside of the fence/curtilege was 
fair game and did not require a 
warrant 
1967: 
Katz v United States
Decided in favor of Katz, making 
wagers using a bugged public 
telephone (expectation of privacy)
2008:
First seeds accepted at the 
Svalbard Seed Bank on 
Spitsbergen Island, Norway
1936: 
Wellcome Trust founded - 
independent charity funding 
research to improve human and 
animal health 
2000: 
Millennium Seed Bank 
Project begins at the Royal 
Botanic Gardens, Kew
2007:
Millennium Seed Bank banks its 
billionth seed
2009: 
Millennium Seed Bank reaches its 
10% goal of banking all the world’s 
wild plant species
1976:
Researchers begin preserving 
frozen animal specimens at the 
“FROZEN ZOO” at San Diego Zoo 
Conservation research center
2006:
Generation Scotland launches the first 
population and family-based Scottish collection 
of biological samples
2010:
Generation Scotland reaches 10,000 
participants
2010:
UK Biobank passes its 500,000-
participant target
1996: 
deCODE Genetics, Inc. founded to 
identify human genes associated 
with common diseases using 
population studies.
2009:
deCODE Genetics, Inc. files for 
bankruptcy
2007:
deCODEme service launched by 
deCODE for Direct-to-Consumer 
genetic testing for 45 common 
diseases
2006: 
Personal Genome Project (PGP) initiated by 
Harvard University Professor George 
Church - Project publishes full genotype, 
phenotype, and personal information on 
the internet
1962:
Robert Ettinger publishes “The 
Prospect of Immortality,” proposing 
that freezing people would be a 
way to benefit from future medical 
technology
1964:
Ettinger’s book published by 
Doubleday
1965:
“Cryonics” term coined by Karl 
Werner, student at Pratt Institute
1965:
Cryonics Society of New York 
founded by Curtis Henderson and 
Saul Kent
1966:
Cryonics Societies of Michigan and 
California formed
1969:
Bay Area Cryonics Society Founded
1976:
Ettinger founds 
Cryonics Institute 
and Immortalist 
Society non-profits
1967:
FIRST CRYONIC SUSPENSION: Dr. James 
Bedford, 73-year-old psychology 
professor (still frozen today at Alcor)
1979:
Nine bodies stored by CSC head 
Robert Nelson discovered to have 
thawed - he was sued and lost
1972: 
Alcor Society for Solid 
State Hypothermia 
non-profit founded by Fred 
and Linda Chamberlain
1986:
Eric Drexler, MIT engineer, published 
“Engines of Creation,” including a chapter 
on cryonics applications
1993:
Splinter group from Alcor founds 
the CryoCare Foundation
1999:
CryoCare disbanded, two patients 
relocated to Alcor
1966: 
CryoTech company established to 
cryogenically freeze metal objects 
and tools to extend their lifespans 
and strengths
2005:
University of Pittsburgh’s Safar Center for 
Resuscitation Research successfully replaced 
dogs’ blood with a low-temperature solution. 
After three hours of being held in stasis 
(clinically dead), the blood was returned to the 
dogs’ bodies, and the dogs were revived using 
an electric shock
2006:
Doctors at Mass General Hospital 
successfully placed pigs in suspended 
animation by anesthetizing, removing 
half their blood, replacing with chilled 
saline solution, then replacing the blood 
while warming the body - 90% success
1971: 
George Martin proposes 
neuropreservation in a speculative 
scientific paper
2005:
KrioRus established outside Moscow 
by eight Russian cryonicists
1978: 
Cryovita Laboratories founded 
by Jerry Leaf at UCLA
1988: 
TIMOTHY LEARY is first celebrity to 
sign up for preservation with Alcor 
*later switched to CryoCare, then 
abandoned plans
2002:
Ted Williams, baseball star, 
placed in cryonic suspension at 
Alcor
1993:
First private cord-blood bank, 
The Biocycle Corporation, set 
up in Connecticut
2008:
GINA - Genetic Information 
Nondiscrimination Act 
signed
1993:
California Supreme Court decides 
Johnson v Calvert in favor of 
biological mother of the infant, not 
the surrogate
1964:
Evan Cooper founds the Life 
Extension Society (LES)
BIOBANK TIMELINE
Biobanks have existed for a long time, in many 
forms. Most important to many of these collections 
has been the advent of preservative technologies. 
With deep freezing and additives, many samples 
like blood and sperm can be frozen for extreme 
amounts of time.
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2003:
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previously cause of the majority of 
transfusion reactions.
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Avery, McLeod and McCarty 
demonstrate DNA is the hereditary 
material.
1953:
WATSON AND CRICK 
describe the double helical 
structure of DNA.
1972:
Cohen and Boyer develop 
recombinant DNA 
technology.
1974:
Issuing of Belmont Report on use 
of human subjects in research.
1983:
First human disease gene mapped 
with DNA markers - Huntington’s 
Disease.
1984:
First public discussion of 
sequencing the human genome.
1986:
Muscular dystrophy gene identified 
by positional cloning.
1988:
Human Genome Organization (HUGO) 
formed.
1989:
Cystic fibrosis gene 
identified by positional 
cloning.
1990:
Human Genome Project (HGP) 
launched in the US. 
First gene for breast cancer 
(BRCA1) mapped.
1992:
Second-generation 
human genetic map 
developed.
1998:
Incorporation of 30,000 genes into 
human genome map.
Chinese National Human Genome 
Centers (in Beijing and Shanghai) 
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1998:
Iceland’s Bill on a Health Sector 
Database passed (HSD)
*(Jan. 1999, fully approved Act)
JUNE 26, 2000
DRAFT OF HUMAN GENOME SEQUENCE FINISHED - 
President Clinton and Prime Minister Blair support new 
stem cell research projects.
2001:
Draft version of human 
genome sequence 
published.  
2003:
Finished version of human genome 
sequence established. 
2003:
Nearly 20,000 people opted 
out of the Icelandic Health 
Sector Database 
(statistically significant)
1999:
Full-scale human sequencing begins.
1995:
US Equal Employment Opportunity 
Commission issues policy on genetic 
discrimination in the workplace.
1996:
First human gene map established.
1978:
LOUISE BROWN, the first IVF live 
birth, born through research by 
Steptoe and Edwards, Greater 
Manchester, UK.
1973:
Transient biochemical pregnancy 
reported by Australian Foxton 
School researchers
1976:
Ectopic pregnancy reported 
by Steptoe and Edwards
1983:
The first pregnancy derived 
from a cryopreserved 
embryo reported by Alan 
Trounson and Linda Mohr
1980:
Sweden bans anonymous sperm 
donation
2010:
UK clinics forced to confirm that a 
limit of 10 children may be born 
from a single sperm donor
AUGUST 23, 2010
US District Court Judge Royce Lamberth 
reinterprets the federal ban on embryo 
destruction to encompass all research 
involving embryos.
MARCH 9, 2010
PRESIDENT OBAMA signs new stem 
cell research legislation, permitting 
greater institutional freedom. 1973: UNIFORM PARENTAGE ACT
“If a wife is artificially inseminated with donor semen 
under a physician’s supervision and her husband’s 
written consent, the husband is recognized legally as 
the natural father.”
1993:
Manhattan Family Court ruled 
against sperm donor Thomas 
Steel’s paternal rights
1990:
UK’s Human Fertilisation and 
Embryology Act - Licensing of 
clinics and protection of sperm 
donors from legal responsibility for 
their resulting biological children.
1983:
The first successful transfer of a 
fertilized egg from one human to 
another - Harbor UCLA Medical 
Center, Dr. John Buster
2009:
McD v L - Ireland Supreme Court 
ruling granting a sperm donor 
visitation rights to a child born via 
artificial insemination
1980:
First successful retrieval of sperm 
from a cadaver, from a brain-dead 
30-year-old man following a motor 
vehicle accident.
1998:
First successful conception using 
sperm retrieved post-mortem
1996:
Dolly the Sheep born : the first 
mammal to be cloned from an adult 
somatic cell using nuclear transfer. 
Because Dolly was cloned from a 
mammary gland, she was named 
after the “famously curvaceous” 
Dolly Parton
2007:
Grand Chamber of the European Court 
of Human Rights rules against Natalie 
Evans in her battle to be inseminated 
with embryos stored when she was 
married to Howard Johnston
2001:
George W Bush established federal policy restricting 
the federal funding of hESC research to research 
conducted on cell lines created before that date. 
1980:
Bayh-Doyle Act - Allows federally 
funded research institutions to 
profit from their discoveries, and 
to patent individual gene lines
1990:
California Supreme Court - Moore 
v. The Regents of the University 
of California - Plaintiff provided 
Leukemia tissue samples that were 
used to create a patented cell line 
- ended up just providing clearer 
informed consent language
2003:
Greenberg v Miami Children’s 
Hospital Research Institution - 
donors attempted to get royalties 
once a research had patented a cell 
line - they were denied
2007:
Washington University v Catalona - Prostate 
cancer research donors did not have rights to 
their samples 
1998: 
California v Greenwood - Narcotics 
ring broken up based on warrant-
less searches of trash left on the 
curb. Decision that the trash 
outside of the fence/curtilege was 
fair game and did not require a 
warrant 
1967: 
Katz v United States
Decided in favor of Katz, making 
wagers using a bugged public 
telephone (expectation of privacy)
2008:
First seeds accepted at the 
Svalbard Seed Bank on 
Spitsbergen Island, Norway
1936: 
Wellcome Trust founded - 
independent charity funding 
research to improve human and 
animal health 
2000: 
Millennium Seed Bank 
Project begins at the Royal 
Botanic Gardens, Kew
2007:
Millennium Seed Bank banks its 
billionth seed
2009: 
Millennium Seed Bank reaches its 
10% goal of banking all the world’s 
wild plant species
1976:
Researchers begin preserving 
frozen animal specimens at the 
“FROZEN ZOO” at San Diego Zoo 
Conservation research center
2006:
Generation Scotland launches the first 
population and family-based Scottish collection 
of biological samples
2010:
Generation Scotland reaches 10,000 
participants
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UK Biobank passes its 500,000-
participant target
1996: 
deCODE Genetics, Inc. founded to 
identify human genes associated 
with common diseases using 
population studies.
2009:
deCODE Genetics, Inc. files for 
bankruptcy
2007:
deCODEme service launched by 
deCODE for Direct-to-Consumer 
genetic testing for 45 common 
diseases
2006: 
Personal Genome Project (PGP) initiated by 
Harvard University Professor George 
Church - Project publishes full genotype, 
phenotype, and personal information on 
the internet
1962:
Robert Ettinger publishes “The 
Prospect of Immortality,” proposing 
that freezing people would be a 
way to benefit from future medical 
technology
1964:
Ettinger’s book published by 
Doubleday
1965:
“Cryonics” term coined by Karl 
Werner, student at Pratt Institute
1965:
Cryonics Society of New York 
founded by Curtis Henderson and 
Saul Kent
1966:
Cryonics Societies of Michigan and 
California formed
1969:
Bay Area Cryonics Society Founded
1976:
Ettinger founds 
Cryonics Institute 
and Immortalist 
Society non-profits
1967:
FIRST CRYONIC SUSPENSION: Dr. James 
Bedford, 73-year-old psychology 
professor (still frozen today at Alcor)
1979:
Nine bodies stored by CSC head 
Robert Nelson discovered to have 
thawed - he was sued and lost
1972: 
Alcor Society for Solid 
State Hypothermia 
non-profit founded by Fred 
and Linda Chamberlain
1986:
Eric Drexler, MIT engineer, published 
“Engines of Creation,” including a chapter 
on cryonics applications
1993:
Splinter group from Alcor founds 
the CryoCare Foundation
1999:
CryoCare disbanded, two patients 
relocated to Alcor
1966: 
CryoTech company established to 
cryogenically freeze metal objects 
and tools to extend their lifespans 
and strengths
2005:
University of Pittsburgh’s Safar Center for 
Resuscitation Research successfully replaced 
dogs’ blood with a low-temperature solution. 
After three hours of being held in stasis 
(clinically dead), the blood was returned to the 
dogs’ bodies, and the dogs were revived using 
an electric shock
2006:
Doctors at Mass General Hospital 
successfully placed pigs in suspended 
animation by anesthetizing, removing 
half their blood, replacing with chilled 
saline solution, then replacing the blood 
while warming the body - 90% success
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George Martin proposes 
neuropreservation in a speculative 
scientific paper
2005:
KrioRus established outside Moscow 
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by Jerry Leaf at UCLA
1988: 
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*later switched to CryoCare, then 
abandoned plans
2002:
Ted Williams, baseball star, 
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The Biocycle Corporation, set 
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Nondiscrimination Act 
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1988: 
TIMOTHY LEARY is first celebrity to 
sign up for preservation with Alcor 
*later switched to CryoCare, then 
abandoned plans
2002:
Ted Williams, baseball star, 
placed in cryonic suspension at 
Alcor
1993:
First private cord-blood bank, 
The Biocycle Corporation, set 
up in Connecticut
2008:
GINA - Genetic Information 
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signed
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biological mother of the infant, not 
the surrogate
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Evan Cooper founds the Life 
Extension Society (LES)
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1915:
Richard Lewisohn at Mount 
Sinai Hospital in New York 
City developed the use of 
sodium citrate as an 
anticoagulant, allowing blood 
to be stored outside the 
body for later transfusion.
1915:
Richard Weil demonstrated 
the refrigerability of 
anticoagulated blood, 
allowing it to be preserved 
for long periods of time.
1917:
During World War I, Oswald Hope 
Robertson, a US ARMY officer 
established a “blood depot” in 
Britain. He is recognized as the 
creator of the first blood bank.
1930:
The Soviet Union 
established 60 large blood 
centers with nearly 500 
smaller subsidiaries for the 
storing and shipping of 
“canned blood.”
1937:
Bernard Fantus, at the Cook County 
Hospital in Chicago started the first 
“blood bank,” leading to the 
establishment of similar facilities in 
hospitals across the United States.
1940:
Willem Johan Kolff opened the first 
blood bank in Europe.
1943:
JF Loutit and Patrick L. Mollison 
introduced acid-citrate-dextrose 
(ACD) solution, which improved 
anticoagulation and storage time for 
blood samples.
1950:
The plastic bag was introduced by Carl 
Walter and WP Murphy as a replacement 
for glass bottles, improving the efficiency 
of blood collection and safety during 
storage. Separation of blood components 
is also promoted by this move. 
1979:
CPDA-1, a new anticoagulant 
preservative was introduced. This 
decreased wastage and facilitated 
resource sharing between blood 
banks.
1939:
Karl Landsteiner, Alex Wiener, Philip 
Levine, and R.E. Stetson discovered 
the Rh blood group, which was 
previously cause of the majority of 
transfusion reactions.
1944:
Avery, McLeod and McCarty 
demonstrate DNA is the hereditary 
material.
1953:
WATSON AND CRICK 
describe the double helical 
structure of DNA.
1972:
Cohen and Boyer develop 
recombinant DNA 
technology.
1974:
Issuing of Belmont Report on use 
of human subjects in research.
1983:
First human disease gene mapped 
with DNA markers - Huntington’s 
Disease.
1984:
First public discussion of 
sequencing the human genome.
1986:
Muscular dystrophy gene identified 
by positional cloning.
1988:
Human Genome Organization (HUGO) 
formed.
1989:
Cystic fibrosis gene 
identified by positional 
cloning.
1990:
Human Genome Project (HGP) 
launched in the US. 
First gene for breast cancer 
(BRCA1) mapped.
1992:
Second-generation 
human genetic map 
developed.
1998:
Incorporation of 30,000 genes into 
human genome map.
Chinese National Human Genome 
Centers (in Beijing and Shanghai) 
established.
1998:
Iceland’s Bill on a Health Sector 
Database passed (HSD)
*(Jan. 1999, fully approved Act)
JUNE 26, 2000
DRAFT OF HUMAN GENOME SEQUENCE FINISHED - 
President Clinton and Prime Minister Blair support new 
stem cell research projects.
2001:
Draft version of human 
genome sequence 
published.  
2003:
Finished version of human genome 
sequence established. 
2003:
Nearly 20,000 people opted 
out of the Icelandic Health 
Sector Database 
(statistically significant)
1999:
Full-scale human sequencing begins.
1995:
US Equal Employment Opportunity 
Commission issues policy on genetic 
discrimination in the workplace.
1996:
First human gene map established.
1978:
LOUISE BROWN, the first IVF live 
birth, born through research by 
Steptoe and Edwards, Greater 
Manchester, UK.
1973:
Transient biochemical pregnancy 
reported by Australian Foxton 
School researchers
1976:
Ectopic pregnancy reported 
by Steptoe and Edwards
1983:
The first pregnancy derived 
from a cryopreserved 
embryo reported by Alan 
Trounson and Linda Mohr
1980:
Sweden bans anonymous sperm 
donation
2010:
UK clinics forced to confirm that a 
limit of 10 children may be born 
from a single sperm donor
AUGUST 23, 2010
US District Court Judge Royce Lamberth 
reinterprets the federal ban on embryo 
destruction to encompass all research 
involving embryos.
MARCH 9, 2010
PRESIDENT OBAMA signs new stem 
cell research legislation, permitting 
greater institutional freedom. 1973: UNIFORM PARENTAGE ACT
“If a wife is artificially inseminated with donor semen 
under a physician’s supervision and her husband’s 
written consent, the husband is recognized legally as 
the natural father.”
1993:
Manhattan Family Court ruled 
against sperm donor Thomas 
Steel’s paternal rights
1990:
UK’s Human Fertilisation and 
Embryology Act - Licensing of 
clinics and protection of sperm 
donors from legal responsibility for 
their resulting biological children.
1983:
The first successful transfer of a 
fertilized egg from one human to 
another - Harbor UCLA Medical 
Center, Dr. John Buster
2009:
McD v L - Ireland Supreme Court 
ruling granting a sperm donor 
visitation rights to a child born via 
artificial insemination
1980:
First successful retrieval of sperm 
from a cadaver, from a brain-dead 
30-year-old man following a motor 
vehicle accident.
1998:
First successful conception using 
sperm retrieved post-mortem
1996:
Dolly the Sheep born : the first 
mammal to be cloned from an adult 
somatic cell using nuclear transfer. 
Because Dolly was cloned from a 
mammary gland, she was named 
after the “famously curvaceous” 
Dolly Parton
2007:
Grand Chamber of the European Court 
of Human Rights rules against Natalie 
Evans in her battle to be inseminated 
with embryos stored when she was 
married to Howard Johnston
2001:
George W Bush established federal policy restricting 
the federal funding of hESC research to research 
conducted on cell lines created before that date. 
1980:
Bayh-Doyle Act - Allows federally 
funded research institutions to 
profit from their discoveries, and 
to patent individual gene lines
1990:
California Supreme Court - Moore 
v. The Regents of the University 
of California - Plaintiff provided 
Leukemia tissue samples that were 
used to create a patented cell line 
- ended up just providing clearer 
informed consent language
2003:
Greenberg v Miami Children’s 
Hospital Research Institution - 
donors attempted to get royalties 
once a research had patented a cell 
line - they were denied
2007:
Washington University v Catalona - Prostate 
cancer research donors did not have rights to 
their samples 
1998: 
California v Greenwood - Narcotics 
ring broken up based on warrant-
less searches of trash left on the 
curb. Decision that the trash 
outside of the fence/curtilege was 
fair game and did not require a 
warrant 
1967: 
Katz v United States
Decided in favor of Katz, making 
wagers using a bugged public 
telephone (expectation of privacy)
2008:
First seeds accepted at the 
Svalbard Seed Bank on 
Spitsbergen Island, Norway
1936: 
Wellcome Trust founded - 
independent charity funding 
research to improve human and 
animal health 
2000: 
Millennium Seed Bank 
Project begins at the Royal 
Botanic Gardens, Kew
2007:
Millennium Seed Bank banks its 
billionth seed
2009: 
Millennium Seed Bank reaches its 
10% goal of banking all the world’s 
wild plant species
1976:
Researchers begin preserving 
frozen animal specimens at the 
“FROZEN ZOO” at San Diego Zoo 
Conservation research center
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Generation Scotland launches the first 
population and family-based Scottish collection 
of biological samples
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Generation Scotland reaches 10,000 
participants
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2009:
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bankruptcy
2007:
deCODEme service launched by 
deCODE for Direct-to-Consumer 
genetic testing for 45 common 
diseases
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Personal Genome Project (PGP) initiated by 
Harvard University Professor George 
Church - Project publishes full genotype, 
phenotype, and personal information on 
the internet
1962:
Robert Ettinger publishes “The 
Prospect of Immortality,” proposing 
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way to benefit from future medical 
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Ettinger’s book published by 
Doubleday
1965:
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thawed - he was sued and lost
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Alcor Society for Solid 
State Hypothermia 
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Eric Drexler, MIT engineer, published 
“Engines of Creation,” including a chapter 
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Splinter group from Alcor founds 
the CryoCare Foundation
1999:
CryoCare disbanded, two patients 
relocated to Alcor
1966: 
CryoTech company established to 
cryogenically freeze metal objects 
and tools to extend their lifespans 
and strengths
2005:
University of Pittsburgh’s Safar Center for 
Resuscitation Research successfully replaced 
dogs’ blood with a low-temperature solution. 
After three hours of being held in stasis 
(clinically dead), the blood was returned to the 
dogs’ bodies, and the dogs were revived using 
an electric shock
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2006: 
Personal Genome Project (PGP) initiated by 
Harvard University Professor George 
Church - Project publishes full genotype, 
phenotype, and personal information on 
the internet
1962:
Robert Ettinger publishes “The 
Prospect of Immortality,” proposing 
that freezing people would be a 
way to benefit from future medical 
technology
1964:
Ettinger’s book published by 
Doubleday
1965:
“Cryonics” term coined by Karl 
Werner, student at Pratt Institute
1965:
Cryonics Society of New York 
founded by Curtis Henderson and 
Saul Kent
1966:
Cryonics Societies of Michigan and 
California formed
1969:
Bay Area Cryonics Society Founded
1976:
Ettinger founds 
Cryonics Institute 
and Immortalist 
Society non-profits
1967:
FIRST CRYONIC SUSPENSION: Dr. James 
Bedford, 73-year-old psychology 
professor (still frozen today at Alcor)
1979:
Nine bodies stored by CSC head 
Robert Nelson discovered to have 
thawed - he was sued and lost
1972: 
Alcor Society for Solid 
State Hypothermia 
non-profit founded by Fred 
and Linda Chamberlain
1986:
Eric Drexler, MIT engineer, published 
“Engines of Creation,” including a chapter 
on cryonics applications
1993:
Splinter group from Alcor founds 
the CryoCare Foundation
1999:
CryoCare disbanded, two patients 
relocated to Alcor
1966: 
CryoTech company established to 
cryogenically freeze metal objects 
and tools to extend their lifespans 
and strengths
2005:
University of Pittsburgh’s Safar Center for 
Resuscitation Research successfully replaced 
dogs’ blood with a low-temperature solution. 
After three hours of being held in stasis 
(clinically dead), the blood was returned to the 
dogs’ bodies, and the dogs were revived using 
an electric shock
2006:
Doctors at Mass General Hospital 
successfully placed pigs in suspended 
animation by anesthetizing, removing 
half their blood, replacing with chilled 
saline solution, then replacing the blood 
while warming the body - 90% success
1971: 
George Martin proposes 
neuropreservation in a speculative 
scientific paper
2005:
KrioRus established outside Moscow 
by eight Russian cryonicists
1978: 
Cryovita Laboratories founded 
by Jerry Leaf at UCLA
1988: 
TIMOTHY LEARY is first celebrity to 
sign up for preservation with Alcor 
*later switched to CryoCare, then 
abandoned plans
2002:
Ted Williams, baseball star, 
placed in cryonic suspension at 
Alcor
1993:
First private cord-blood bank, 
The Biocycle Corporation, set 
up in Connecticut
2008:
GINA - Genetic Information 
Nondiscrimination Act 
signed
1993:
California Supreme Court decides 
Johnson v Calvert in favor of 
biological mother of the infant, not 
the surrogate
1964:
Evan Cooper founds the Life 
Extension Society (LES)
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INTRODUCTION
All over the world, collections of biospecimens and medical records databases help research-
ers and scientists draw conclusions about disease and genetic mutation. 
These collections are comprised of excised tumors, blood samples, and saliva swabs, and are 
generally the by-product of a hypothesis-guided study into a particular topic. 
At the same time, and for the quite different purposes of fertility treatment, life extension, 
and life-saving transfusions, other types of collections are being amassed at sperm banks, 
cryobanks, and blood banks. 
And, while they may not be expressly bound for biobanks, all sorts of samples and biometric 
data, like fingerprints, facial recognition metrics, and newborn baby blood stamps, are being 
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Audubon Center for Research 
into Endangered Species
Sun Health Research Institute
National Human Genome 
Research Institute
European Bioinformatics Institute
Kew Millennium 
Seed Bank
California Cryobank
San Diego “frozen zoo”
CARTaGENE
Generation Scotland, Edinburgh
Vaesterbotten Swedish Project
Singapore Genome Database Project
# subjects: 400,000
budget: US $4M
funding: state/foundation
biospecimens: yes
data: yes
government: major state 
involvement
P3G (Public Population Project in Genomics)
consortium of four collaborative databases
Personalized Medicine 
Research Project
HapMap
# subjects: 400
budget: US $100M
funding: public/private
biospecimens: yes
data: yes
government: none
DeCode Biobank
DeCode Genetics (pvt)
GRAD (Howard U.)
# subjects: 270,000
budget: US $800K/year
funding: private agreement 
between DeCode, Roche, and 
Merck.
biospecimens: yes
data: yes
government: supervision for 
consent protocol
# subjects: 25,000 (African 
descent)
budget: US $18M
funding: NIH and Industry
biospecimens: yes
data: yes
government: major involvement in 
planning 
Tonga Kingdom (Autogen)
# subjects: 108,000
budget: NS
funding: private
biospecimens: yes
data: yes
government: major, considered 
responsible for failure
UK Biobank (Ltd.)
# subjects: 500,000
budget: US $109M/year
funding: public
biospecimens: yes
data: yes
government: administered by 
National Health System
Estonian Genome Project
# subjects: 1,065,000
budget: NS
funding: public/private 
agreement with EGeen for 
25-year access
biospecimens: yes
data: yes
government: highly involved
GenomEUtwin
# subjects: 80,000 (twins)
budget: NS
funding: public EU funds
biospecimens: yes
data: yes
government: mainly interna-
tional collaboration
Latvian Genome Project
# subjects: 60,000
budget: US $405,000/year
funding: public/public
biospecimens: yes
data: yes
government: major new 
legislation
Biobank Japan (U.Tokyo)
# subjects: 300,000
budget: US $215M/5 years
funding: public/private
biospecimens: yes
data: yes
government: major investment
collected and recorded constantly by private 
security firms, law enforcement, and public 
health officials. 
Most large biobank projects are begun with 
specific research aims in mind, and are funded 
either privately by stakeholders who stand 
to profit from the venture, like DeCode in 
Iceland, or by public sources that have money 
earmarked for research into specific types of 
studies, like Kaiser Permanente in California. 
These narrowly focused ventures may sat-
isfy individual research aims, but they don’t 
feed information back into a forum where it 
can continue to contribute to the public good. 
All of these projects and companies regard 
their surveyed data as proprietary informa-
tion, as a type of investment capital, for 
which they reserve the right to compensa-
tion. Individuals have periodically lobbied for 
royalties on drugs or discoveries patented 
using their base material, but this is a short-
sighted view of medical data’s transformative 
economic potential, actually supports existing 
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ownership structures, and have been repeat-
edly rejected by the Supreme Court. 
The tight hold that researchers have on 
their data once their studies have been com-
pleted represents a detrimental dead end, 
and is a function of complex archaic funding 
structures that need to change. It is in this 
forum of productive use for dead ends that 
the most research potential is housed, since, 
as ventures like the Personal Genome Proj-
ect have shown, the most meaningful sta-
tistical data is that in which all aspects of 
an individual’s genotype, their genetic code, 
and phenotype, their biometrics like CT scans 
and MRIs, as well as health history and envi-
ronmental exposure, can be cross-referenced 
and compared. The more metrics, the better. 
A new American institution is needed to har-
ness the power of all this information – the 
Biobank for America. 300,000,000 biospeci-
mens are already being stored today across 
the country. Collectively, they represent a 
unique storehouse of information from which 
trends may be retroactively extrapolated. 
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The information is out there – it’s not a 
question of wanting to share personal infor-
mation or not. At this point, it’s how we, as a 
country, choose to use the information that 
is already being collected, doing very little 
for those from whom it is taken. 
The Biobank is more than a repository, it be-
comes a monument to collective heritage, and 
a proactive stance against the way informa-
tion is traded now. It is an investment in the 
discoveries of the future and a movement 
towards transparency. 
The consolidation of this archive under the 
auspices of governmental regulation subse-
quently devalues the potential harm it can 
do to any one individual and forestalls an 
information economy like that already under 
construction with Google’s HEALTH applica-
tion. As has been shown by George Church, 
anonymity in medical research is neither in-
tellectually productive, nor practically pos-
sible. 
Steps like the 1998 Genetic Informational 
Nondiscrimination Act (GINA) indicate trend-
ing of thought in this direction, as we slowly 
catch on to the hazards of a lopsided entry 
into a new territory of biological information 
availability. 
The Biobank consolidates material and data, 
certainly, but it also articulates a nation-
al position on public support for discovery 
and innovation, and against an old model of 
counterproductive information economies. The 
Biobank for America is an antidote and a 
projection for a productive future. 
300,000,000 biospecimens exist in collections across the US 
right now. Slowly, certain biobanks are creating networks 
and building collaborations. The Biobank for America will 
consolidate all of these collections into one searchable and 
accessible national monument.
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GENETIC INFORMATION NONDISCRIMINATION ACT
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While many biobanks exist all over the world, 
their different purposes and conditions of 
creation mean that their administrations 
and business models differ widely. From 
this range, a few examples can serve to 
show the diversity of their approaches – 
some models deal directly with the public as 
‘consumers,’ of medical data and information, 
some models work with existing data that has 
yet to be collated into meaningful statistical 
conclusions, and some models intend to create 
an entirely new storehouse of information by 
collecting carefully detailed reports moving 
ahead. I will look at a four such examples in 
the effort to explain the extremes against 
which the Biobank for America proposes an 
alternative. 
The Direct-to-Consumer range of collections 
are not necessarily called biobanks, though 
they fit my definition. These companies 
traffic in genetic testing and genomic 
products sold directly to the consumer, 
removing the traditional middle-man of a 
medical professional. Typically, one orders 
a testing kit online to be completed at 
home and returned to a testing facility. A 
quick search of Amazon.com in January of 
2011 reveals a variety of different at-home 
testing kits, including those to determine the 
“breed identification” of a dog, paternity of a 
child, ancestry, and predisposition for certain 
inherited diseases. On Henry Louis Gates Jr.’s 
PBS series, “Faces of America,” a number 
of different public personalities (including, 
famously, Malcolm Gladwell, along with Stephen 
Colbert, Eva Longoria, Yo-Yo Ma and Meryl 
Streep) submitted their DNA to be tested for 
markers of different geographic and ethnic 
heritages – the company contracted to do 
these tests was 23andMe, a four-year old 
venture in California, and the results were 
supposed to be illuminating of some American 
Condition. 
By contracting directly with those who 
THE STATE OF THINGS
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submit saliva and blood samples to provide 
information about predisposition to disease 
or ancestry, 23andMe strategically avoids the 
traditional medical establishment. Because 
of this unorthodox entry into quasi-medical 
information collection and dissemination, the 
direct-to-consumer genetic testing market 
has come under considerable scrutiny in the 
past year. While companies like 23andMe do 
not call themselves biobanks, they certainly 
collect information and biospecimens that 
would be useful in one. Further, they make no 
promises to their customers about disposal 
of the material they supply. While customers 
may be assured privacy by virtue of not 
supplying any identifying information with 
their sample, this, as George Church rightly 
points out, is a false notion of confidentiality 
– at this moment, where assigned codes like 
social security numbers and names are what 
we consider our identity, it is difficult to 
imagine a time where the genetic code itself 
might supercede all of these earlier markers. 
Another type of biobank is that whcih 
sets out expressly to collect data or to 
merge existing databases. The examples of 
Kaiser Permanente in California and deCODE 
Genetics in Iceland are similar in this way. 
While they both actively collect new data, 
both companies saw an opportunity in data 
that already existed, Kaiser Permanente in 
its own insurees health care records, and 
deCODE in the meticulous multi-generational 
‘Book of Icelanders.’ In these examples, 
the particular politics by which existing 
databases get collated and integrated are 
essential. For Kaiser Permanente, a private 
insurer employing in-network health care 
practitioners, it was a matter of convincing 
their clients to participate in a study for 
the public good. For deCODE, the Icelandic 
Health Care Database represented a cache of 
information that was difficult to opt out of. 
The commercial gains and research aims of 
these two projects are quite different, but 
their strategies in tackling the sticky issues 
of obtaining consent for the use of existing 
data are instructive. 
Finally, a biobank quite different from the 
previous three is that of the Personal 
Genome Project. George Church’s venture 
at Harvard set out to fully sequence the 
genomes of a trial group of ten subjects. 
In contrast to the direct-to-consumer model, 
where a user receives unmediated information 
directly from the laboratory, all participants 
in the Personal Genome Project receive the 
results of their sequencing through a trained 
genetic counselor. After this extensive 
discussion, the participant then decides 
whether or not, and in what manner, to share 
this information, with the default being total 
public disclosure on the internet. Dr. Church 
believes in this small sample study as a 
model for a much broader and encompassing 
one. Eventually, he contends, the general 
public will become so conversant in informed 
consent and genomic policy that researchers 
will not need to grapple with the ethical and 
moral implications of genomic privacy control. 
In this sense, the Personal Genome Project 
looks much more strongly forward than back. 
Whereas deCODE and Kaiser Permanente seek 
to mine their existing resources as new fonts 
of information, the PGP readily acknowledges 
the inadequacies that existing databases 
can have and projects a new type of totally 
open data collection and distribution. Part 
of Church’s decision to create entirely 
new stores of information for this project 
was based on the fact that very few data 
keeping standards exist for medical histories 
and comparable metrics. Starting fresh means 
creating new data points that all fall on the 
same graph, it means a more comprehensive 
and useful biobank. 
The pleasure of reconceiving the idealized 
biobank scenario comes from imagining along 
with it a climate of public acceptance and 
comprehension that might grow up around a 
concerted nation-wide effort to collect data 
and inspire public thought. Part of my hope 
in discussing the ways in which these existing 
models work is to expose the inadequacies of 
current thought on the topic. Even George 
Church, pioneer of what might come off as 
a radical open-source biomedical ideology, 
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must tailor his ideas and programs to fit the 
concerns about privacy and identity of today. 
23andMe, Direct-to-Consumer (DTC) Models:
In the summer of 2010, the FDA opened 
hearings to investigate the new crop of 
direct-to-consumer genetic testing companies 
popping up all around the country. Despite 
the highly technical and advanced techniques 
being used in these operations, there was 
little, if any, oversight from the government, 
and practically no method by which to ensure 
the quality of results reached between 
different testing companies. As David Gurwitz 
and Yael Bregman-Eschet point out a year 
before the investigations began, “the FDA 
should inspect the quality and accuracy 
of DTC personal genomics tests whereas 
the FTC should provide oversight over 
the accuracy of advertized claims made by 
companies offering these tests.”1  Even voices 
from within the industry itself appealed to 
the FDA, asking for guidance and a measure 
of public credibility. What the FDA found 
was ultimately damning for the direct-to-
consumer industry, taking the wind out of 
1 David Gurwitz and Yael Bregman-Eschet, “Personal Genom-
ics Services: Whose Genomes?” in European Journal of Human 
Genetics, Vol. 17, 883-889, 2009, 887. 
their sails and halting distribution of their 
products for an evaluatory period during 
which the assumptions they make about the 
material they analyze would be put under 
scientific scrutiny. Shortly before the FDA 
ruling, Walgreens, a popular national drug 
store chain, had agreed to carry direct-to-
consumer genetic testing products directly 
in its store, eliminating at least one arm of 
the mail-order internet business and making 
them more accessible and attractive to the 
general population. 
Another interesting potential of the direct-
to-consumer market is the medium in which 
customers receive the results of their 
genetic tests. Using unique identifying codes, 
these users can sign in to a secure website 
and access information about the geography 
of their heritage, their susceptibility to 
certain diseases, and even preventative 
medical treatments available. Taking it one 
step further, this can be understood as a 
type of biobank of data on the internet. 
If a customer accesses her results online, 
there is no reason not to further extend 
the range of tools at her fingertips to find 
information or to share in a community of 
SAMPLE 
COLLECTION 
KIT
JULY 2010 FDA HEARINGS ON DIRECT-
TO-CONSUMER GENETIC TESTING COMPA-
NIES FIND RESULTS UNRELIABLE AND 
POTENTIALLY HARMFUL
$50 - $400
FULLY ENCRYPTED 
DATA
23andMe model. 
The Direct-to-Consumer model calls for little oversight of 
genetic sequencing results, and because of that has caught 
flack from the FDA - at this point, the technology is too 
young to give results with certainty.
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like-gened individuals.“Users can . . . . utilize 
social networking tools to join forces with 
fellow risk group members: Genetic testing 
meets Facebook. More recently, Google, 
which has invested in both 23andMe and 
Navigenics, launched a tool for individuals 
to store health records online and hopes 
to eventually expand its activities, including 
its search capabilities, to the genetic testing 
market.”2 By collapsing personal data 
collection into social networking and including 
health records, Google, with its ‘Health’ 
application, could have access to the largest 
voluntary trove of medical information in the 
world. Very quickly, the type of information 
that might be seen as private and limited 
to the person to which it relates becomes a 
tool of connection to other individuals. Once 
this hurdle is accomplished, the creation of 
a large-scale networked biobank database 
practically takes care of itself. 
One of the reasons that the FDA objected 
to the widespread advertizing of these 
2 David Gurwitz and Yael Bregman-Eschet, “Personal Genom-
ics Services: Whose Genomes?” in European Journal of Human 
Genetics, Vol. 17, 883-889, 2009, 883. 
home-testing products is that they can’t 
yet prove valid undisputed conclusions. 
“The US Government Accountability Office 
presented results from a damning year-
long investigation into the DTC gene-testing 
industry that characterized some of the 
tests as ‘misleading’ and ‘of no practical 
use,’ and the marketing surrounding them as 
deceptive and fraudulent.”3 The science is 
simply too young, the understanding is simply 
too thin to be able to say with certainty that 
particular constellations of genes correlate 
absolutely with the types of generalized 
outcomes that the public expects. Further, 
they don’t provide professional genetic 
counseling, something that is understood as 
necessary for lay-people receiving results 
that may have bearing on their health care 
and understanding of mortality.  Consider, 
for example, the possibility of receiving word 
that you carry the hereditary breast cancer 
gene BRCA-1 without a doctor present. When 
will I fall ill? Will it be fatal? How can I 
prepare for this event? These questions are 
3 Alla Katsnelson, “Consumer Gene Testing in the Hotseat; 
A Week of Hearings Sows Uncertainty for the Fledgling Con-
sumer Genomics Industry,” in Nature Genetics Online. 
3.3 MILLION KP NETWORK MEMBERS
HEALTH CARE NETWORK
RPEGH = RESEARCH PROGRAM ON GENES, 
ENIVIRONMENT, AND HEALTH
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TO MEET INSTITUTE ON 
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NO DATA
Kaiser Permanente Model:
The Kaiser database represents a huge resource for bio-
bankers, but their scope is limited to the 65+ members of 
the network because of grant-giving priorities.
31
difficult for an untrained person to answer, 
and are potentially damaging to experience 
without guidance. 
KAISER PERMANENTE
The biobank at Kaiser Permanente has a 
different set of concerns, and is much less 
controversial than its Californian neighbors 
in the direct-to-consumer testing business, 
perhaps because it’s a closed-network concern. 
“A striking feature of this project is that, 
as a health-care insurer, Kaiser Permanente 
recruits the participants from amongst its 
members, that is, its own insurees, and uses 
the data that have been stored in its archives 
for almost four decades. This is a typical case 
of new research on extant data for which re-
consent will be sought.”4 Attempting to mine 
their own store of medical records, Kaiser 
Permanente seeks to create new connections 
between environmental pollutants, exercise, 
and disease. This type of plainly beneficial 
research aim allows the company to request 
clearance from participants, offering 
them only the knowledge that they have 
participated in a kind of vague betterment 
of society. Interestingly, this type of large-
scale collation of data is exactly the most 
robust type of research possible now – the 
linking of genotype (genetic sequencing) and 
phenotype (measured biometrics including 
environmental factors). 
Unfortunately, because of funding structures, 
Kaiser Permanente is not able to draw 
together as much information as they have 
access to. “The NIH’s National Institute on 
Aging has taken a leading role in providing 
funds for this grant in part because the 
average age of those whose DNA will be 
genotyped is 65, which has significant 
ramifications for research into healthy aging 
and age-related disease.”5 Because most 
medical research relies on public grants for 
support, even the most information-rich 
4 Lunshof, Jeantine E, Ruth Chadwick, Daniel B. Vorhaus and 
George M. Church, “From Genetic Privacy to Open Consent,” in 
Nature Reviews Genetics, Vol. 9, May 2008, 408. 
5 Robert Wood Johnson Foundation website, www.rwjf.org. 
Accessed 4:21pm 18 July 2010.
resources like Kaiser Permanente are forced 
to adjust their research priorities to fit the 
goals of its funders. Because NIH was willing 
to back the construction of this biobank 
through its Institute on Aging, the biobank 
will concentrate its efforts on collecting data 
from an older population, a population which 
comprises only about 35% of their clients. 
While their work is important and will no 
doubt begin to return useful hypotheses, it 
is only a fraction of what could be learned 
from a true population-based survey with 
fewer limits on its scope. 
deCODE
Kari Stefansson, the charismatic director of 
deCODE Genetics in Iceland, famously left 
academic research at Harvard because of a 
frustration with the clinical samples he was 
able to orchestrate. With studies generally 
conducted like small-scale versions of that 
at Kaiser Permanente, there are too many 
factors limiting the nature of the data and 
the possible uses for it to be fully useful, he 
contends. This and the fact that his native 
Iceland is a historically isolated population, 
more or less consistent and well-recorded. 
Unfortunately, deCODE has been plagued by 
allegations of malfeasance as it engages at 
once with the medical records and genetic 
codes of an entire public and contracts 
with private ventures expressly for profit. 
“Critics point to the special relationship 
that has evolved between deCODE and the 
Icelandic government. They also point out 
that the Icelandic parliament’s decision to 
grant deCODE exclusive rights (for 12 years) 
to the information included in the nation’s 
health-records database – in accordance with 
Iceland’s Act on a Health Sector Database 
(1998) – raises questions having to do with 
fairness and equal access.”6
Before beginning research in earnest, 
deCODE, a private company with headquarters 
in Reykjavik but incorporated in Delaware, 
6 Herman T. Tavani, “Genomic Research and Data-Min-
ing Technology: Implications for Personal Privacy and 
Informed Consent,” in Ethics and Information Technol-
ogy 6, 2004, 17. 
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secured an agreement with the Icelandic 
Parliament for exclusive rights to access the 
Icelandic Health Sector Database. There have 
been numerous suggestions that deCODE 
was behind significant confidential donations 
to each parliamentary party in excess of 
$300K. Further, deCODE entered an exclusive 
contract with the Swiss pharmaceutical giant 
Roche, receiving $200M for the rights to 
all discoveries and drugs developed in the 
same twelve-year period. Similarly, deCODE 
established an agreement with IBM “to sell 
jointly an integrated computer system that 
combines deCODE’s proprietary ‘gene-mining’ 
software with IBM’s servers and database 
software.”7 Throughout this period of deal-
making, the Icelandic people were offered only 
the joy of contributing to the betterment of 
public health. When pressed by journalists 
for answers, Roche, standing to benefit 
through patented gene sequences and new 
drugs, vaguely promised the Icelandic people 
free access to preventative diagnostics and 
drugs developed through the agreement 
with deCODE. Without a timeline or a clear 
7 Herman T. Tavani, “Genomic Research and Data-Mining 
Technology: Implications for Personal Privacy and Informed 
Consent,” in Ethics and Information Technology 6, 2004, 18. 
contract for how this exchange might take 
place, this is an empty promise and only 
encourages a reading of this private venture 
as dishonest. When deCODE went public in 
2008, enough Icelanders had taken steps to 
‘opt out’ of the Health Sector Database to 
be statistically significant. In 2009, deCODE 
declared bankruptcy and shifted most of its 
continuing practice to focus on direct-to-
consumer genetic testing. 
Ignoring for a moment the ethical and moral 
conflicts that Stefansson has found his 
project engaged in, the fact remains that if 
deCODE had managed to find a way to bring 
together all of its available information in 
a comprehensive way, their collection would 
have represented one of the most robust 
genetic resources in the world. Despite 
Stefansson’s best efforts to publicize his 
own interest in informed consent, widespread 
public distrust and investigative journalists 
ultimately brought the project down. In a 
paper published in the New England Journal 
of Medicine, Stefansson directly confronts 
criticisms of his operation: “Why should 
Icelanders trust a private company to 
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The Direct-to-Consumer model calls for little oversight of 
genetic sequencing results, and because of that has caught
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protect their personal health information? 
It is probably better for a private company 
to hold this information than for the state 
to do so, since governments can violate 
the privacy of individuals to advance the 
interests of society as a whole. Moreover, if 
a health care data base managed by a private 
company violates privacy, the company can be 
closed down. According to the Icelandic law, 
deCODE will lose the license to develop and 
use the data base if the conditions of the 
license, including the stipulations regarding 
the protection of privacy, are not met.”8 In 
his formulation of the problem, the public 
is indeed safer knowing that their private 
medical records are held by a private company 
which is overseen by the government rather 
than by the government itself. Peculiarly 
convincing though this structure may seem, 
it was not convincing either to the Icelandic 
people or to the American medical research 
establishment. 
PROPERTY / PROPRIETARY INTERESTS
One of the most interesting and still 
ambiguous aspects of biobanking is the 
question of property – who owns the right 
to what material and for how long? Who can 
profit in what way, and if bodily material 
is involved, does it matter who it originally 
came from? These questions continuously 
plague biobanking projects, to mixed results. 
The general consensus in medical journals is 
that a complicated game of informed consent 
must be played, but there is little agreement 
on how best to obtain this level of educated 
permission from clients or contributors, 
and even less about how it plays out 
through time. This question of property and 
permission is further confounded when large 
sums of money are involved in a biobanking 
venture, as they were in the early start-
up days at deCODE. In their anthropological 
examination of the genomics industry, Paul 
Rabinow and Gisli Palsson touch on just this 
moment of public fixation. “The dominant 
8 Jeffrey R Gulcher and Kari Stefansson, “The Icelandic 
Healthcare Database and Informed Consent,” in The New Eng-
land Journal of Medicine. Boston: Vol. 342, Iss. 24, 1827. 
outside focus has been on issues that are 
often elided: the fact that a private company 
proposes to construct a genomic map of the 
Icelandic people (as part of a State-owned 
and operated database) and to commercialize 
information contained in it. This strategy has 
been confused (with more or less good faith) 
with ‘selling Icelandic DNA.’”9 
These property conflicts came to light most 
of all in the deCODE case, mainly because so 
much money was in play. The involvement of 
Roche and the campaign finance allegations 
exposed in the Icelandic press make the 
intentions behind the creation of the deCODE 
biobank seem less than honest or purely 
for the benefit of research. As Stefansson 
himself points out in his decision to abandon 
the academic research establishment for his 
private venture, more money buys a more 
robust research pool of information. Many 
times, entrepreneurship and the allure of 
great profit is the only thing that spurs 
wide-ranging meaningful innovation – this 
does not prove that it is the best model for 
research, only the most successful in this 
funding climate. 
The deCODE case is only an extreme example, 
one that highlights biological property rights 
issues that have been emerging over the 
past decade. As Richard Spinello points out 
in his resume of recent decisions in genetic 
property rights cases, the conflicts are quite 
clear in Iceland because all of the players are 
easily distinguishable in their intentions and 
what they stand to gain from the venture. 
“If we deny that Iceland’s citizens have a 
proprietary right in their genetic source 
material for the greater good of scientific 
research, it seems contradictory to assert 
that deCODE Genetics should have a de facto 
property right by virtue of its exclusive 
access to this information and its ability to 
reap the lion’s share of the rewards. Neither 
the Iceland Government nor deCODE Genetics 
should be vested with a quasi-property 
9 Gisli Palsson and Paul Rabinow, “Iceland: the Case of a 
National Human Genome Project,” in Anthropology Today, Vol. 
15, No. 5 (October 1999), 15. 
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interest that gives them exclusive, custodial 
control over this research data.”10 It has 
taken a long time to develop public opinion 
about property rights in these matters. Many 
of the decisions that are used as precedents 
in genetic specimen rights cases were made 
long before the technology in question was 
developed. 
Decisions pertinent to these issues include 
California v. Greenood (1988), Moore v. 
Regents of the University of California 
(1990), Greenberg v. Miami Children’s Hospital 
Research Institute, Inc. (2003), and Washington 
University v. Catalona (2008). In Greenwood, 
it was decided that any material abandoned 
or left in a place that was the equivalent to 
abandonment was rightfully public property, 
and therefore liable to search without a 
warrant: “the Fourth Amendment does not 
prohibit the warrantless search and seizure 
of garbage left for collection outside the 
curtilege of a home. It further stated 
that any claimed expectation of privacy in 
the inculpatory items discarded was not 
reasonable. Once the items were discarded, 
any constitutional right to privacy in those 
items has been abandoned.”11 It is this type of 
logic by which material is termed abandoned 
once it leaves an area under strict supervision. 
It is what allows criminal prosecutors to test 
discarded cigarette butts and soda cans for 
DNA samples, entering them in vast criminal 
databases without violating Americans’ fifth 
amendment right to avoid self-incrimination. 
The Moore case is a little bit more complicated 
because there is a hint of malfeasance – 
while undergoing treatment for a hairy-cell 
leukemia, John Moore provided a variety of 
tissue samples meant to be used in research 
to find a cure for his disease.12 13 What is not 
10 Richard A. Spinello, “Property Rights in Genetic Informa-
tion,” in Ethics and Information Technology 6: 29-42, 2004, 
40. 
11 Marcia J. Weiss, “Beware! Uncle Sam Has Your DNA: Legal 
Fallout From Its Use and Misuse in the U.S.” Ethics and 
Information Technology Vol 6, 2004, 61. 
12 Richard A. Spinello, “Property Rights in Genetic Informa-
tion,” in Ethics and Information Technology 6: 29-42, 2004, 
35. 
13 Lisa C. Ikemoto, “Eggs as Capital: Human Egg Procurement 
known is if those samples would have been 
encouraged by his doctor had he not stood 
to profit through patented pharmaceuticals 
and treatments developed. Regardless of the 
intent, the California Supreme Court ruled 
that “individuals do not have an ownership 
interest in their cells after the cells have 
been removed from their bodies.”14 Similarly, 
in the Greenberg case, parents discovered 
that their children’s cell lines had been 
used to develop patented drugs at the 
Miami Children’s Hospital Research Institute. 
Seeking compensation or a percentage of the 
profit found from these samples, Greenberg 
was ultimately struck down, with the 
understanding that to allow patients property 
rights to their tissue samples would sap the 
strength of financial research incentives. 
Finally, the judicial decisions on these cases 
share one unexpected strain – they do not 
universally acknowledge the sanctity of the 
body or the boundaries of personal property 
as defining these cases. What they look to is 
the precedent that allowing citizens to hold 
property rights over their biological material 
might set – a potentially paralyzing situation 
for medical research in all its forms. If every 
cell line were, in effect, copyrighted, the 
ease with which research is performed on 
a diverse store of material might disappear. 
Looking toward the “public good,” which is 
what “research” is broadly understood 
to represent, these court decisions land 
unanimously against personal property rights 
to biological samples. The complicated logic 
that then allows them to agree that these 
cell lines may then become the property of 
scientists who stand to profit from patented 
drugs is almost impossible to understand, 
except again in light of that same cryptic 
elision of “public good,” and “research.” 
These decisions set up a de facto free-
market biomedical economy, with little room 
in the Fertility Industry and the Stem Cell Research Enter-
prise,” in Signs: Journal of Women in Culture and Society, 
Vol. 34, No. 4, The University of Chicago, 2009, 778. 
14 Karen J. Maschke, “Chapter 3: Biobanks: DNA and Re-
search,” in From Birth to Death and Bench to Clinic; The 
Hastings Center Bioethics Briefing Book for Journalists, 
Policymakers, and Campaigns, ed. Mary Crowley. Garrison, NY: 
The Hastings Center, 2008, 12. 
35
or reason to adapt to a changing climate. 
This massaging of property claims with an eye 
toward research implications is abundantly 
clear in the evolution and development of 
certain genetic privacy and anti-discrimination 
laws. As Richard Spinello points out: 
“Oregon’s Genetic Privacy Act of 1999 boldly declared 
that genetic information was an individual’s personal 
property. The Oregon legislature saw proprietary 
rights as the key to securing privacy protection when 
it enacted that landmark legislation. But researchers 
and scientists complained that the assignment of a 
proprietary right to each individual’s genetic information 
(including their genetic code) would be a major obstacle 
to genetic research. As a result, the law was modified 
in 2001 – the property interest was removed, though 
criminal penalties would still be imposed for the 
misappropriation of genetic data.”15
Once again, “research” is seen as a 
common good, and any financial incentives 
that researchers claim are understood to 
ultimately protect and encourage universal 
gain. 
15 Richard A. Spinello, “Property Rights in Genetic Informa-
tion,” in Ethics and Information Technology 6: 29-42, 2004, 
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THE PERSONAL GENOME PROJECT
George Church, the dynamic founder of the 
Personal Genome Project, has a number of 
new and sometimes controversial ideas about 
privacy in medical research. If the greatest 
public benefit can be found in collating all 
types of genetic and historic information 
about a patient, especially through time, then 
perhaps our current notions about separating 
the person from their metrics is flawed. In 
most clinical trials now, and even in the 
huge UK Biobank still in its collection phase, 
participants are assigned a unique identifying 
number, and databases linking these 
numbers to traceable civilian information like 
social-security number and name are kept 
separate and highly guarded. In the journal 
Nature Reviews Genetics, a subset of the 
powerhouse Nature conglomerate, George 
Church along with a number of other genetics 
professionals published their findings on how 
this type of privacy is actually an elaborate 
illusion. “There is increasing evidence from the 
medical and bioinformatics fields that indicates 
that absolute privacy and confidentiality is 
not a promise that medical and scientific 
ALL DATA RETURNED TO PARTICIPANTS
(OPPORTUNITY TO REDACT BEFORE
PUBLICATION ON INTERNET)
TRAINED GENETIC 
COUNSELORS
BROAD INSTITUTE, 
HARVARD & MIT GOOGLE COUQ FOUNDATION ORBIMED NIH NHGRI CEGS
APPLIED 
BIOSYSTEMS AGENCOURT HELICOS
LYNX: 
SOLEXA/ILLUMINA
COMPLETE 
GENOMICS, INC.
PERSONAL GENOME
PROJECT 
GENETIC SEQUENCING
FUNDING WITHOUT 
DIRECT OR EXCLUSIVE 
PERMISSIONS
Personal Genome Project Model:
With the PGP, all participants have their full genome se-
quenced and the results are posted online along with other 
biometric results. Importantly, participants are given the 
opportunity to redact any information before it goes online.
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researchers can deliver.”16 Because databases 
fail and because confidentiality can never be 
100 percent  guaranteed, he urges for a shift 
in public anxiety about disclosure. “We argue 
that the reality of the new genetics and 
genomics urges us to abandon the traditional 
concept of medical confidentiality. As we 
hold the view that ethical thinking evolves 
alongside science, we argue that new models 
are needed to offer robust moral guidance 
while keeping the reality of a dynamic science 
in mind.”17 Indeed, much like in the genetic 
property rights cases discussed above, a new 
definition of the public good must be weighed 
against traditional ideas about privacy and 
the threats of medical disclosure. 
The Personal Genome Project started with 
a trial group of ten participants, including 
professionals in the genetics and genomics 
field, those who could be assured to have 
the highest level of knowledge about the 
risks they were taking and the consent that 
they were granting. Church himself is among 
this first wave. Each participant’s DNA was 
sequenced, and extensive medical histories 
and tests were taken, in order to provide 
the broadest picture of individual health. 
The project’s model dictates that as findings 
emerge in the sequencing, the participant is 
introduced to the implications and meanings 
through a trained genetic counselor. This is 
an important stage in the PGP procedure, 
first because it creates yet another point 
at which data may be translated into true 
medical implications (for example, if you have 
such-and-such a gene mutation, you are 
statistically x percent more likely to develop 
y disease), and second because it provides the 
participant with the option to either share 
this information publicly or to omit it from 
their online record. This method promotes the 
maximum level of consent-granting possible 
for a study of this size because each finding 
16 Lunshof, Jeantine E, Ruth Chadwick, Daniel B. Vorhaus and 
George M. Church, “From Genetic Privacy to Open Consent,” 
in Nature Reviews Genetics, Vol. 9, May 2008, 407. 
17 Lunshof, Jeantine E, Ruth Chadwick, Daniel B. 
Vorhaus and George M. Church, “From Genetic Privacy 
to Open Consent,” in Nature Reviews Genetics, Vol. 9, 
May 2008, 406. 
is treated as a separate decision. 
The PGP can be seen almost as a meta-
study, in the way that we think about 
funding medical research. Church and his 
team are not setting out to find the cure 
for a particular type of cancer, they’re not 
starting with a hypothesis to prove, they are 
collecting information for information’s sake, 
so that they might build as complete and 
robust a store of health data as possible. 
In interviews, of course, Church states many 
reasons why this might be beneficial to the 
public and sponsors alike, not in the least 
because he has challenged genetic sequencing 
machinery manufacturers to keep pace with 
his ambitions and bring the cost of sequencing 
an individual’s genome down by factors of ten. 
Without affordable testing, huge population-
based sequencing would be impossible. 
Unless, of course, you are a private company 
engaged in complicated exclusive transactions 
with pharmaceutical companies – unless you 
are deCODE, essentially. 
Church operates within biomedical research 
in another revolutionary way. He does not 
oppose the privatized research arms of 
companies like Celera or deCODE, but he does 
not promote them either. In an interview I 
conducted with him in July 2010, he stated his 
policy to me clearly – he is in the knowledge 
business, but he’s also not stupid. To work 
purely for enlightened non-profit aims is 
ultimately detrimental to the research; it 
cannot be done for free. To work entirely 
for-profit means that certain anxieties arise 
about property rights and compensation. To 
work in the open-source mode is another thing 
entirely, and he embraces this multi-pronged 
allegiance throughout all of his projects. 
The PGP is sponsored by multiple competing 
private and public companies. Similarly, Church 
works in an advisory capacity on a number 
of competing startups, 23andMe included. He 
believes that all these different ventures 
push the industry and the science towards 
new levels of efficiency and accessibility. 
Starting with a small test group, the PGP 
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has expanded rapidly, with more than 
fifteen thousand volunteers willing to share 
their most intimate medical and identifying 
information widely. All findings are reported 
on the project’s internet site, fully accessible 
and usable in whatever manner by the public. 
The key, he believes, is in quantity, and with 
quantity comes a lessening risk to individuals. 
“Society at large [Church] says, doesn’t really 
know how to handle most genetic information. 
‘I’m trying to make sure that there’s enough 
information at a low enough risk to that all 
of the stakeholders in this technology, now 
or in the near future, will have a test set to 
work with,’ Church says.”18 Lowering this risk 
means changing public opinion about what risk 
means, and pressuring lawmakers to provide 
protection for those who choose to share, 
18 Erika Check Hayden, “Meet Exhibit 1; George Church Has 
Made a Name for Himself as an ‘Information Exhibitionist,’” in 
Nature, Vol. 45, 14 February 2008, 763. 
or who are subject to the sharing of, that 
information. Addressing public concern over 
potential fallout from genetic findings, Dr. 
Church assured me that GINA, the Genetic 
Information Nondiscrimination Act, had a great 
effect on his test subjects, himself included.19 
With the advent of GINA, he claimed, very 
few participants could object to disclosure 
of their genetic sequences on grounds of 
potential discrimination – their objections 
could be reduced to fear of exposure and 
the implications certain findings might have 
for their close relatives.20 
19 For a couple of recent pop-culture examples of the 
anxiety surrounding what is sometimes seen as the predic-
tive nature of genetic sequencing, try Andrew Niccol’s 1997 
Gattaca or Steven Spielberg’s 2003 Minority Report. In both 
films, genetics are understood to be analogous with fate 
– characters are imprisoned by their genetic identities or 
similar predictive qualities, and in both, the triumph of a 
hero rejecting his imposed fate provides the storyline. 
20 The relative question is actually not unimportant – the 
implications of finding one genetic mutation can extend 
George Church is a Rock Star: 
www.nytimes.com/2010/06/08/science/08church.html
accessed 4 January 2011 2:39pm
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PRIVACY, GINA, PROTECTION
“After innumberable iterations, more than 12 
years of development and 224 cosponsors, 
the Genetic Information Nondiscrimination 
Act (GINA) was signed into law on May 21, 
2008....The bill, which targets insurers and 
employers, prohibits the use of genetic 
information to set health insurance premiums, 
deny coverage or affect employment.”21
More than any legislation or promise of 
confidentiality, there is power in data itself, 
in quantity. Much like Hasan Elahi, the Rutgers 
professor and artist who documents his 
life through photographs and GPS readings 
and posts this stream online in a quasi-
performance-art piece of protest against 
(and for) government surveillance, the PGP 
project suggests a new type of information 
independence – inundation.22 Elahi subverts the 
government’s interest in him by providing them 
with more information than could possibly be 
processed. Mistakenly confused for someone 
on the FBI’s watch list, Elahi found himself 
throughout a family. This was a major concern in Iceland’s 
HSD because while individuals were able to opt out for 
themselves, they were not able to posthumously opt out of 
the database for recently deceased relatives or for children 
too young to give consent. 
21 Nature Biotechnology Editorial, Vol. 26, No. 6 June 2008. 
22 Clive Thompson, The Visible Man: An FBI Target Puts His 
Whole Life Online. Wired, Vol. 15, No. 06, 22 May 2007. See 
http://TrackingTransience.net. 
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constantly accounting for his movements. As 
an artist, this type off performance piece 
in response is surely appealing, especially 
with the resistant political implications it 
carries. But this strategy might represent a 
productive way forward for issues of medical 
disclosure as well. George Church certainly 
believes so – he argues that “if everyone 
finds that he or she carries some genetic 
risk, as is likely to be the case, people 
may not think others’ risks are such a big 
deal.”23 GINA is a response to current threats 
in a current mindset. It is a response to 
a concern, a treatment of a symptom, but 
not a solution to the problem. It has been 
hailed as “the first major civil rights act 
of the 21st Century,” and that certainly may 
be so, but for how long?24 What freedoms 
does it protect, and what constructs does 
it promote? Rather than accounting for 
pieces of information one-by-one, focusing 
on isolated threats, would it not be better to 
abandon old notions of privacy and to build a 
new collective store of information founded 
on disclosure?
23 Erika Check Hayden, “Meet Exhibit 1; George Church Has 
Made a Name for Himself as an ‘Information Exhibitionist,’” in 
Nature, Vol. 45, 14 February 2008, 765. 
24 David Gurwitz and Yael Bregman-Eschet, “Personal 
Genomics Services: Whose Genomes?” in European Journal of 
Human Genetics, Vol. 17, 883-889, 2009, 886. 
The Biobank for America:
In a new model, private and public funds are brought to-
gether and all data is shared, effectively ending a false 
expectation of confidentiality.
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CONCLUSION: 
The advent of genetic sequencing has meant 
that biospecimens that were once inert 
records in medical collections are again 
relevant. Historic sample collections like the 
brains amassed by Harvey Cushing over his 
career as a physiologist and brain surgeon, 
or tissue samples held in hospital pathology 
departments for the purposes of comparison 
can tell researchers new things about the 
past. Over 300 million biospecimens exist in 
the United States alone, most of them not in 
cutting-edge current biobanks like the PGP 
or at pharmaceutical companies – they are 
in small-scale cold storage. The problem is 
that most projects where a clinical study is 
conducted, where specimens might be collected 
and stored, are funded by grants to fill a 
certain purpose. As in the Kaiser Permanente 
biobank, where NIH funds earmarked for 
research into older patients shaped the 
clinical pool for the project, many small 
collections were established with specific 
ends in mind. This re-finding of samples in 
plain sight is a goldmine of information and 
is not being ignored. “Population biobanks 
that were previously used in epidemiology 
or in anthropology in an academic context 
are now of utmost interest to industry 
for pharmacogenetic applications. Similarly, 
collections of tissue biopsies that were of 
no other use than for individual diagnosis or 
clinical follow-up are now the source of new 
information for gene expression studies.”25
It is clear that new medical technology is 
making more information available than 
ever, and in many new ways. This calls for 
a wholesale rethinking of the way we deal 
with medical information. This idea is slowly 
building steam in the medical community and 
different methods of managing research and 
coordinated biobanks are being proposed. 
What seems to make the most sense, learning 
from the examples of the companies and 
ventures described above, is a system that 
25 Anne Cambon-Thomsen, “The Social and Ethical Issues of 
Post-Genomic Human Biobanks,” in Nature Reviews Genetics, 
Vol. 5, November 2004, 867. 
brings a combination of private and public 
funding together – basically a plurality in 
sponsors, much as how George Church is 
always sure to line up conflicts within his 
funding and advising pool. The plurality of 
funders is matched with an excess of outlets 
– a revolutionary transparency. Across the 
board, it seems that the greatest benefit 
would be reaped from the greatest exposure 
of information and influence within a biobank. 
The Biobank for America takes this to heart, 
and consolidates the 300 million existing 
biospecimens in the United States to make 
them accessible, visible, and present in the 
national public conscious.26 Looking at the 
current climate, this seems like a major 
dramatic shift. Considering the changes that 
have taken place in the past ten years, 
and the giant leap this type of collection 
would represent for the country, a total 
restructuring of the field does not seem 
quite so impossible. 
26 R. Lewontin. It Ain’t Necessarily So. London: 
Granta, 2000, 182. 
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RESEARCH
What you just read wasn’t intentional, and 
it’s not the end either. If I am completely 
honest with myself, then yes, I was maybe 
overly excited about my thesis topic when 
I started learning about deCODE. When I 
found that so many different types of 
biobanking projects were being funded by 
so many different sources, I was psyched. 
This provided me entry into a topic in the 
shoes of an investigative reporter. Fur-
ther, it was easy to pick sides, especially 
when one of the sides can be called “the 
common good,” or “the public.” 
It wasn’t just an alibi, I had stumbled on a 
real reason for doing the project I was go-
ing to do anyway, and I couldn’t stop read-
ing. I wouldn’t necessarily reccommend this 
-- there is a time for research and a time 
for design -- but it was enormously satis-
fying to learn about a new field, figure out 
how it ailed, and propose a solution. 
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DESIGN
What follows is what I’ve done over the 
course of this project. Some of it is final 
work that I showed at the thesis review, 
and some of it never made it off of my 
desk, until now. 
Things are arranged roughly by topic -- 
site, program, strategy, etc. -- but not 
entirely. These stripey pages are my ver-
sion of a director’s cut, a commentary I am 
giving during the show. I hope it won’t be 
distracting. In fact, I hope it will enhance 
your understanding of how I got to certain 
places in my work and how certain things 
fell through the gaps. 
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NEWARK INTERNATIONAL AIRPORT
LIBERTY STATE PARK, NJ
PORT NEWARK/ELIZABETH
BROOKLYN MARINE/RED 
HOOK CONTAINER TERMINAL
Liberty State Park, July 2010
Downtown Jersey City and Lower Manhattan visible in the 
distance. 
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SITE
The Biobank for America is situated in north-
ern New Jersey, at what is presently the un-
derused former brownfield of Liberty State 
Park. It is a site with considerable regional 
history, as its development was sponsored 
by steady landfilling since the mid-1800s with 
material excavated for under-Hudson tun-
nels. It was a rail yard and shipping depot 
right up until its designation as a state park 
in 1976, and has been left largely unman-
aged and unprogrammed since, despite pe-
riodic plans for Jersey City extensions and 
additional recreational facilities. 
With the historic CRRNJ terminal just on the 
waterfront, this site is already a stop on the 
New York Harbor ferry route, which includes 
Ellis Island and the Statue of Liberty. 
This is an ideal situation for the Biobank 
and its attendant intention of promoting 
biobanking itself and inspiring confidence in 
the American people. To situate it in such 
proximity to historic hertiage monuments is 
to enocourage a reading of it that is some-
how already embedded in the nation’s historic 
consciousness. Map of Liberty State Park and environs:
Newark International Airport, Port Elizabeth, and Lower 
Manhattan in close proximity.
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1881 LANDLINE
1966 LANDLINE
1887 LANDLINE
1974 AND PRESENT LANDLINE
c.1923 development proposal
Map of Liberty State Park site through time, showing grad-
ual landfilling and the 1923 plan to extend streets down 
from Jersey City
Archival maps of the site through time. 
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The Liberty State Park site has had a rich 
industrial history, and is unusual for its size 
and usage in the area. This small harbor was 
steadily landfilled over time and became a 
shipping and transit depot connecting directly 
across New York Harbor to lower Manhat-
tan via ferry. As the under-Hudson tunnels 
and the George Washington Bridge started to 
take on some of the transit volume, this site 
became even more fully devoted to industrial 
shipping and cargo loading activities. 
As you can see in the multi-era map on the 
left, landfilling of the site did not happen 
in one fell swoop, it was gradual, meaning 
that material sunk into the surrounding har-
bor has had time to settle and achieve a 
more structural support capacity than typical 
landfilling sites. 
As the shipping industry looked to greener 
pastures in the larger cargo dogs of Newark 
and Port Elizabeth, a number of proposals 
were put forward to street this site and ex-
tend Jersey City south into it. While none of 
those came to pass, the memory of proposed 
street grids remains as a reminder of what 
the site might have been. 
The site as it looks today, and as an active rail depot in 
the 1910s. 
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New England Treatment Plant Cumberland, RI
Newtown Creek Treatment Plant, Greenpoint
Riverbank State Park, NYC
Stericycle Treatment Facility, Stoughton, MA
Stericycle Treatment Facility, Woonsocket, RI
REGULATED MEDICAL WASTE
RMW is waste that comes from hospitals, 
veterinary clinics, dentists’ offices, spas, and 
other therapeutic locations. It is a special 
type of waste because it contains possibly 
infectious material. In the State of New Jer-
sey, producers of RMW are required to have 
a destruction plan in place: either they have 
treatment facilities on site (as in most large 
hospitals), or they contract with a firm to 
cart waste off-site to a registered destruc-
tion location. 
There are currently only thirty facilities in 
the State of New Jersey that are registered 
to treat and destroy their own Regulated 
Medical Waste, and zero facilities engaged in 
Commercial RMW Treatment. All small-scale 
RMW producers have their waste picked up 
and shipped out of state, primarily to Penn-
sylvania. 
Because RMW is legally required to be chemi-
cally or high-temperature treated to become 
sterile and non-infectious, RMW landfills are 
actually significantly cleaner than typical 
landfills, where material is not treated prior 
to being set into the ground. 
Semi-urban waste treatment facilities. Of particular inter-
est are the Newtown Creek and the Riverbank State Park 
plants, because they are within New York City. Riverbank 
in particualr manages to combine a water treatment facility 
with a recreational park. 
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RITE Project v5 
Proposed additional power 
AQUACULTURE AND TIDAL POWER
Because the East River and the waterways 
surrounding it are tidal, water is constantly 
moving and changing directions. A project be-
gun five years ago in the East River places 
tidal power-harvesting turbines on the river 
floor that can rotate and twiste to catch the 
greatest amount of tidal movement. 
This is an opportunity to use the Liberty 
State Park site productively, not just as a 
sanctuary for endangered Lower New York 
Harbor wildlife like the North Atlantic Stur-
geon, but as a real generator of energy. By 
cutting into the site to expose areas of open 
water, the Biobank for America can foster 
aquaculture at the same time as finding the 
energy to power its own heating and cooling 
systems. 
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1:10,000
Site Plan, initially 1:2000
49
Considering the rich history of this site and 
its present disuse (this state park is largely 
unusable by the public -- only the promenade 
portion along the river is fully accessible to 
visitors), this is a great opportunity to bring 
Northern New Jersey back into a national 
monument conversation with other sites in 
the Lower New York Harbor area. 
The site is designed to have a number of 
different user experiences within it. Areas 
for aquaculture are bordered by recreational 
paths along the east side of the site. From 
these paths, a more ‘wild’ synthetic nature 
experience is visible by extending the dis-
tance a person might walk along the pe-
riphery and also orienting the viewer’s gaze 
outwards over the water and towards lower 
Manhattan. 
In the central portion of the site, small 
geometric mounds are visible. This corridor 
also represents foot travel between docking 
ferry boats and the biobank itself, and is 
the primary natural vista that visitors would 
encounter. 
Of course, these geometric mounds serve the 
purpose of bolstering the ground against sea 
level rise at the harbor level, but they also 
contain the landfilled RMW constantly being 
brought to the site. This material, because 
it is sterile, serves as excellent berming 
matter and echoes the biospecimen-positive 
ethos present in the biobank nearby. All of 
these specimens, be they blood samples or 
dirty bandages from surgery, have a useful 
place at the Biobank for America. 
SITE PLAN PROPOSAL
Site Model showing berming strategy and relationship to 
the shoreline. 
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Ossuary at the San Cataldo Cemetery, Modena, Italy
Aldo Rossi’s ossuary at the San Cataldo Cemetery is a four-storey 
structure centrally located within the cemetery complex which houses human 
remains within its own walls. Each case is sealed within the wall perma-
nently, but each closing panel remains open to the air and accessible to 
touch. All walls are only one-case-deep.
Yale Cushing Center Brain Collection
Glass jars filled with brains, brain samples, or tumors 
immersed in formaldehyde are clearly labeled and arrayed 
throughout a display area behind thick UV-protective 
glass. Every brain in the collection is visible, but none 
are accessible.
The collection is the work of the early neurosurgeon 
Harvey Williams Cushing, who developed new techniques 
for skull removal and tumor treatment.
Yale Cushing Center Brain Archive
Glass jars filled with brains, brain samples, or tumors immersed 
in formaldehyde are clearly labeled and arrayed throught a 
display area behind thick UV-protective glass. Every brain in the 
collection is visible, but none are accessible. 
The collection is the work of the early neurosurgeon Harvey 
Williams Cushing, who developed new techniques for skull re-
moval and tumor treatment. 
Ossuary at the San Cataldo Cemetery, Modena, Italy
Aldo Rossi’s ossuary at the San Cataldo Cemetery is a four-
storey structure centrally located within the cemetery com-
plex which houses human remains within the walls. Each case 
is sealed within the wall permanently, but each closing panel 
remains open to the air inside and accessible to visitors’ touch. 
All walls are only one case deep. 
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Looking at programming relationships be-
tween archives and varying degrees of public 
access, three main strains emerge that might 
be of use for a new type of biobank.
One is a level of visibility and contact - 
something that is present to different de-
grees in the Yale Brain collection and Rossi’s 
San Cataldo Ossuary. In these examples, the 
public and the architecture have a direct 
physical relationship with the material being 
stored. 
A one-to-one experience of quantity and di-
rect connection cannot be overrated, espe-
cially in the case of this biobank. I am trying 
to, in contrast to collections like the UK Bio-
bank or deCODE, create a direct phsyical con-
nection between the public and the samples 
that they invariably supply. At Yale, a user 
can visually inspect each brain in the collec-
tion, though of course they are off-limits for 
actual handling. At San Cataldo, relatives of 
the deceased know where to find their loved 
one, each entry in this cemetery biobank has 
an address, a location where a physical rela-
tionship might be focussed. 
PRECEDENTS AND LESSONS
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The Library of Congress, Washington, D.C.
Entry into the largest library in the United States requires 
multiple levels of security and identity-verification clearance. 
Tourists are permitted to take a very limited tour without 
verification, but they do not approach any of the stacks or 
historic reading rooms. All researchers are required to obtain 
special Library of Congress identification, which states the 
nature of their research and the duration of their library 
access. 
Books must, as in the New York Public Library, be requested at 
a central circulation desk. All specialty reading rooms require 
additional identification and clearance.
The Library of Congress, Washington, D.C.
Entry into the largest library in the United States requires 
multiple levels of security and identity-verification clearance. 
Tourists are permitted to take a very limited tour without 
verification, but they do not approach any of the stacks or 
historic reading rooms. All researchers are required to obtain 
special Library of Congress identification, which states the 
nature of their research and the duration of their library 
access. 
Books must, as in the New York Public Library, be requested at 
a central circulation desk. All specialty reading rooms require 
additional identification and clearance.
Svalbard Global Seed Vault, 
Svalbard Mountains, Norway
The Svalbard Seed Bank partners with seed banking institu-
tions worldwide to preserve their unique stock of heritage 
and wild seeds. Seed banking differs slightly from practices 
like DNA banking because the seeds need to be replanted and 
recollected periodically in order to maintain their fertility. The 
Svalbard Seed Bank is not responsible for this practice, and 
instead stores only sealed packets of seeds in its temperature-
controlled vaults deep inside the permafrost of the remote 
Svalbard mountains. 
The Library of Congress, Washington, D.C.
Ent y int  the largest library in the United States requires 
multiple levels of security and ide tity-v rification clearance. 
Tourists are permitted to take a very limited tour without veri-
fication, but they do not approach any of the stacks or historic 
reading rooms. All researchers are required to obtain special 
Library of Congress identification, which st tes he nature of 
their research and the duration of their library access. 
Books must, as in the New York Public Library, be requested at 
a central circulation desk. All specialty reading rooms require 
additional identification and clearance. 
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Gifu Research Laboratories of Amano Enzyme, Inc.
Gifu Prefecture, Japan
The Gifu labs incorporate an open workbench environment with 
two floors of overlooking offices, all nested around a steeply 
raked topography. Researchers are visiually accessible, and of-
fice/research relationships are organized by field group.
Novartis Campus
Basel, Switzerland
This laboratory, representative of the philosophy of the No-
vartus campus that researchers and developers must maintain 
constant contact, integrates informal meeting spaces as well as 
high-tech laboratory space, allowing a more livable lab environ-
ment. Further, the openness is occasionally broken for periodic 
facilities, avoiding a sense of vastness. 
The notion of the collective, or its opposite 
- total security - are present at the Library 
of Congress and Svalbard Seed Bank. Here, 
material is stored in a mass out of sight of 
the public, but its presence remains the iden-
tity of the building. 
In some sense, the archive is just a spiritual 
one - the idea that it is there and contains a 
compendium is all that matters. The truth is 
that hardly anyone has access to these two 
archivees, and if they do, they most likely 
are not using them regularly. The Svalbard 
example is further confounded because of 
the role that archivists play in it. Because 
seeds need to be replanted and germinated 
periodically, and because the remote Sval-
bard Seed Bank is unmanned for most of the 
year, hardly anyone ever comes in contact 
with the actual material being stored. Fur-
ther, what is stored is not archival so much 
as short-term savings. 
Finally, an aspect of sectional interaction, 
illustrated in the Novartis labs and in Gifu, 
means that in the regulated environments 
of laboratories, while certain physical sepa-
rations may be necessary because of con-
tamination or temperature concerns, visual 
contact may still be maintained through a 
‘looking down into’ or ‘-across’ strategy. 
The notion of the open lab is important be-
cause much as in the San Cataldo and Yale 
examples, the Biobank for America is about 
transparency. If the public is going to feel 
true ownership or stewardship over the col-
lection, they must have a direct relationship 
to the contents of the archives, the ma-
terial they supply. This logic extends from 
the archived samples to the research work 
going on there as well. A rhythmic system 
of peeks into laboratories and other semi-
private spaces for authorized researchers 
must be worked into the circulational logic 
of the building. 
54
SVALBARD SEED BANK
DEEP COVER
SAN CATALDO OSSUARY
PACKED WALL
LIBRARY OF CONGRESS
STACK SEPARATION
PLANNED PARENTHOOD
SECURITY ZONES
CUSHING BRAIN ARCHIVE
LOOK, DON’T TOUCH
NOVARTIS LABORATORY
OPEN FIELD
SALK INSTITUTE
SANDWICHED 
SERVICES
GIFU RESEARCH 
LABORATORY
LAB BLEACHERS
ATRIUM LABORATORY
NESTED LABS
CLARK LABORATORY
UTILITY CORES
SVALBARD SEED BANK
DEEP COVER
SAN CATALDO OSSUARY
PACKED WALL
LIBRARY OF CONGRESS
STACK SEPARATION
PLANNED PARENTHOOD
SECURITY ZONES
CUSHING BRAIN ARCHIVE
LOOK, DON’T TOUCH
NOVARTIS LABORATORY
OPEN FIELD
SALK INSTITUTE
SANDWICHED 
SERVICES
GIFU RESEARCH 
LABORATORY
LAB BLEACHERS
ATRIUM LABORATORY
NESTED LABS
CLARK LABORATORY
UTILITY CORES
SVALBARD SEED BANK
DEEP COVER
SAN CATALD  OSSUARY
PACKED WALL
LIBRARY OF CONGRESS
STACK SEPARATION
PLANNED PARENTHOOD
SECURITY ZONES
CUSHING BRAIN ARCHIVE
LOOK, DON’T TOUCH
NOVARTIS LABORATORY
OPEN FIELD
SALK INS ITUTE
SANDWICHED 
SERVICES
GIFU RESEARCH 
LABORATORY
LAB BLEACHERS
ATRIUM LABORATORY
NESTED LABS
CLARK LABORATORY
U ILITY CORES
SVALBARD SEED BANK
DEEP COVER
SAN CATALDO OSSUARY
PACKED WALL
LIBRARY OF CONGRESS
STACK SEPARATION
PLANNED PARENTHOOD
SECURITY ZONES
CUSHING BRAIN ARCHIVE
LOOK, DON’T TOUCH
NOVARTIS LABORATORY
OPEN FIELD
SALK INSTITUTE
SANDWICHED 
SERVICES
GIFU RESEARCH 
LABORATORY
LAB BLEACHERS
ATRIUM LABORATORY
NESTED LABS
CLARK LABORATORY
UTILITY CORES
SVALBARD SEED BANK
DEEP COVER
SAN CATALDO OSSUARY
PACKED WALL
LIBRARY OF CONGRESS
STACK SEPARATION
PLA NED PARENTHOOD
SECURITY Z NES
CUSHING BRAIN ARCHIVE
LOOK, DON’T TOUCH
NOVARTIS LABORATORY
OPEN FIELD
SALK INSTITUTE
SANDWICHED 
SERVICES
GIFU RESE RCH 
LABORATORY
LAB BLEACHERS
ATRIUM LABORATORY
NESTED LABS
CLARK LABORATORY
UTILITY CORES
55
DIAGRAMMATIC INTENTIONS
Using these tools as guides, the Biobank for 
America is a public building with a secure 
but visible private component. The archive, 
what the building exists to contain and make 
available to the public, is spread thinly into a 
maximum surface area condition, inhabiting an 
automatically operated thin wall, which also 
serves as structural and conceptual support 
for the building around it. Next, layers of 
public and private programming each have ac-
cess to these walls, interweaving around one 
another with their own circulational systems 
- private (being scientists and other longer-
term employees) traveling vertically through 
the archive walls, and the public employing 
a more side-to-side viewing mode between 
their two floors of laboratories, exhibits, 
classrooms, and the auditorium. 
The friction between these two systems 
comes in the way private laboratories peek 
up and down into public space, offering a 
glimpse of the technical research work being 
done in the building. This ‘peeking’ is also 
sponsored by a mode of alternating, or sand-
wiching infrastrucutral necessities like HVAC 
and chemicals between every other floor, al-
lowing labs to receive these pipes through 
built-in furnishings connecting either over-
head or through the floor. 
Formal Priorities:
Diagrammatic transformation based on precedent concepts. 
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STUDY MODEL GRAVEYARD
It took me a long time to arrive at that conceptual 
diagram for the project, though it seems almost in-
evitable when I look at it next to the examples and 
precedents I was using. The archive posed some 
big kind of metaphorical hurdles for me because I 
wanted to make it at once accessible to and pro-
tected from the public. 
Tilted Test Tubes: I had thought that I might be able to 
create an archive strategy that allowed a shift from a ver-
tical orientation to a more horizontal one, with laboratories 
filling in the space around. 
Woven Programs: This was an idea about circulation through 
the site and through the archive, again keeping certain 
programs separated. 
Pill Towers: I spent a lot of time early in this project 
thinking about ways to move samples within the archive and 
building vertically. This was an idea about columns becoming 
active in moving material about the building. 
Split Blocks: Symbolically, I thought it would be effective to 
show a cluster of pretty small-scaled laboratory buildings 
cleaved in two by a massive and visible archive volume. 
Micro Site-Model: I was very interested early on in develop-
ing a way of making models that not only represented my 
ideas, but also conveyed them materially. The use of dyed 
polyurethane foam was meant to sort of mimic a blood-and-
guts type of biobank viscerality. 
Surrounding Skin: Here, I had thought that perhaps the 
archive could form a wrapped skin around stacked labo-
ratories. 
Double Loop: I was really excited about the possibility of 
keeping two completely separate loops within a single build-
ing, uniting only in the central archive. 
57
A DIP INTO SCIENCE?
I spent a long time tracing and remodeling prec-
edents before I started actually designing anything. 
This, coupled with the fact that I had only vague 
ideas about what types of programs belonged in 
the biobank, and in what quantity, drove me to 
this piece of really unsuccessful form-finding. Of 
course, this type of strategy can be useful, and I 
did end up learning a lot about my priorities from 
this exercise, but the idea that you could take a 
little of this, a little of that, smush it together 
with some vague notions of program and produce 
a building was, admittedly, a little hopeful. This 
diagram was produced shortly after the midterm.
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Stomach Wall Musculature Fatty Liver Open Heart
FORM GRAVEYARD
I began the semester with an idea about form-
finding, or rather a lot of questions about form-
finding. I felt that through all of my projects at 
MIT, I had closed myself off from a lot of formal 
opportunities because some strategies are just 
‘not done,’ or ‘not cool.’ Perhaps this betrays a 
certain insecurity I have about architecture because 
I entered the field late in my education. Why, I 
wondered, do we reject certain modes of investiga-
tion in favor of others? In particular, what’s wrong 
with metaphor? What’s wrong with heavy-handed 
symbolism? What’s wrong with my impulses towards 
the cheesy? What follows is a selection of ideas 
and schemes that I am proud to have explored, and 
probably glad don’t figure in the final product. 
I presented this diagram at my first public review. I had 
been playing around with different ways to make or find 
form, and so it seemed like the type of material in the 
biobank might be a good jumping off point. I’m glad I took a 
look at this, because it satisfied my curiosity, and I’m glad 
it’s out of my system. 
Once again, I was trying to find a way to clearly mark 
the difference between kind of standard biotech laboratory 
spaces and a more surprising space that weaves through 
and around them for the archive. 
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This is where the idea of peeking first came up - I wanted 
a high-bay laboratory, and it seemed like it would be fun to 
aim an amphitheater at it. 
This scheme was also from the first review - I was continu-
ing the idea that there might be a vast underground archive 
that feeds up through a public space, in this case outdoors, 
into laboratories. 
Here I was trying again to explore the more literal cheesy 
side of my impulses - I thought that perhaps I could ab-
stract a DNA chart reading into some kind of a surface 
treatment that might continue throughout the building.
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WALL-BOUND ARCHIVE
DONATION CENTER/ENTRY
LABORATORIES/OPERATIONS
RESEARCH PLATFORM
PUBLIC ASSEMBLYSCAPE
RMW SORTING/DELIVERY
SAMPLE TRANSPORT TUBES
At the mid-review, I still thought that the site might be 
excavated quite deeply, opening up a space for underwater 
tidal turbines, but still exposing a longer shoreline.
Once again, the brief intersection of one program with an-
other is manifest in a geometric disconnect. 
Alongside the spiraling of public and private programs 
around one another, I had thought that the archive could 
act as a tilted sort of core. 
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RIGHT LOOP - LOW CLEARANCE, FULLY OPEN
LEFT LOOP - PARTIALLY RESTRICTED ACCESS
ARCHIVE - PASS-THROUGH ENTRIES
ENCLOSURE VOLUMES HINGED FROM ARCHIVE
SEPARATE AND JOINING LOOPS
LOADING DOCK / SORTING 
STATION
PERMANENT STAFF ENTRY
PUBLIC ENTRY
DONATION CENTER
LABORATORIES
MEDIA SUITE
CAFETERIA
ASSEMBLY/AUDITORIUM
SECURITY CLEARANCE
GYMNASIUM
LOCKER ROOMS
LANDFILL MAINT./ EQUIP. 
STORAGE
REGULATED MEDICAL WASTE 
STEAM STERILIZATION
These two diagrams basically represent me, just after the 
mid-review, finally getting a handle on the programming of 
this building and how certain spaces might lead into one 
another. 
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Wet
Dry
Blood
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Urine
Tissue
Blood
Plasma
Cord Blood
Large Tissue
Head (Cryonic)
Body (Cryonic)
Body (Research)
Amputations
200 samples 1200 samples
24 samples 240 samples
20 samples 100 samples
1 sample 10 samples
1 sample
250 samples 1000 samples
XS
S
M
L
XL
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BAG
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4in
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40in
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PROGRAMMING
There are, of course, a number of different 
types of sample in the biobank, which each 
have different requirements in terms of ac-
cess to transportation, heating and cooling, 
and the size of the individual contents. 
In the diagram below, it is clear that there 
is some kind of scalar relationship between 
the contents of the archive and the way in 
which they are stored. Perhaps because I 
was interested in finding a storage solu-
tion that would support samples of all sizes 
being readily accessible, the notion of au-
tomated storage systems began to take on 
great importance. 
But before the systems came into focus, it 
is important to address certain priorities 
of this biobank. As a location where organs 
might be generated from stored DNA samples 
or where sperm and embryo samples might 
be stored to create a national fertility bank, 
it is important that tranpsortation figure 
prominently in the conceptual layout of the 
project. Identifying these moments of trans-
portation connection, and figuring out which 
ways might be most useful to group samples 
turned out to be extremely useful in laying 
out a conceptual groundwork for the project. 
Sample Storage Strategies for different types of biospeci-
men and different modes of transport. 
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Kiva Systems
‘Smart’ robots move standardized shelves for both 
stocking and picking from a station. Robots manage 
inventory and ‘learn’ which shelves have higher turnover, 
daily schedules, and efficient routes.
Used by Staples, Zappos, and Amazon.com
Edogawa Ward Kasai Bike Parking Tokyo, Japan
Designed by JFE Engineering Corporation
Users can leave their bike and retrieve it in less than one 
minute, regardless of where it is stored within the 
underground cylinder.
MPS Automated Parking Lot 
Flat panel-like robots roll below each car, directing it onto the 
relocation crane. The robots also calculate the nearest available 
parking space. 
Micronic XL100 Test Tube Sorter and Scale
The precision grips are able to select individually addressed 
test tubes from an array, uncap, recap, weigh the contents, 
and re-sort based on weight-based algorithms.
Kiva Systems
‘Smart’ robots move standardized shelves for both 
stocking and picking from a station. Robots manage 
inventory and ‘learn’ which shelves have higher turnover, 
daily schedules, and efficient routes.
Used by Staples, Zappos, and Amazon.com
Edogawa Ward Kasai Bike Parking Tokyo, Japan
Designed by JFE Engineering Corporation
Users can leave their bike and retrieve it in less than one 
minute, regardless of where it is stored within the 
underground cylinder.
MPS Automated Parking Lot 
Flat panel-like robots roll below each car, directing it onto the 
relocation crane. The robots also calculate the nearest available 
parking space. 
Micronic XL100 Test Tube Sorter and Scale
The precision grips are able to select individually addressed 
test tubes from an array, uncap, recap, weigh the contents, 
and re-sort based on weight-based algorithms.
Kiva Systems
‘Smart’ robots move standardized shelves for both 
stocking and picking from a human-manned station. Ro-
bots manage inventory and ‘learn’ which shelves have 
higher turnover, daily schedules, and efficient routines. 
This system is used by Staples, Zappos, and Amazon.
com warehouses. 
Edogawa Ward Kasai Bike Parking, Tokyo
Designed by JFE Engineering Corporation. 
Users can leave their bike and retrieve it in less than 
one minute, regardless of where it is stored within the 
automated underground cylinder. Because humans do 
not need individual access to the cylinder, bikes can be 
parked much closer and more efficiently than in stan-
dard bike rack situations. 
Micronic XL100 Test Tube Sorter and Scale
The precision grips are able to select individually ad-
dressed test tubes from an array, uncap, recap, weigh 
the contents, and re-sort based on weight-based al-
gorithms. This system can be combined with a larger-
scale warehousing system to make all test tubes in a 
collection accessible. 
MPS Automated Parking Lot
Flat panel-like robots roll below each car, directing it 
onto the relocation crane which acts as a giant gantry 
within the parking structure. The robots also calcu-
late the nearest available parking space, maximizing 
efficiency. 
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Public/Private vs. Hot/Cold gradients for samples
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PATHOLOGYDISEASE
FERTILITY
BLOOD AND SALIVA
ORGANS
CRYONICS AND HISTORIC
SAMPLE PROCESSING
MOLECULAR
PUBLIC ACCESS
TISSUE CULTURE
LOADING DOCK
REGULATED MEDICAL 
WASTE TREATMENT
In the Biobank for America, samples are dis-
tributed between six primary categories of 
sample, which correspond to different walls 
which, in turn, are sized to accommodate the 
approximate volume of this material present 
in the US today. The walls contain samples in 
the categories of disease, fertility, blood and 
saliva, organs, historical anomalies, and an 
additional wall for the processing and pack-
aging of samples. 
These categories were determined by look-
ing at the different needs certain types of 
collection have. My initial assumptions about 
temperature proved to open up a whole chap-
ter of my investigation and helped refine my 
ideas about ventilation and flows through the 
project. Rather than a giant walk-in freezer, 
this biobank collection actually wanted a va-
riety of climactic conditions. Some blood sam-
ples and historic slides used for pathology 
are not stored in below-freezing conditions. 
By virtue of the way they were collected, 
some samples can be stored at room tem-
perature. 
Further, the biobank is not just a storage 
facility. It’s has a number of active research 
laboratories as well. In discussion with bio-
tech professionals, I found out that many 
labs that work with tissue culture and stem 
cells actually have whole areas that are cli-
mate controlled to be warm - body-temper-
ature rooms. 
The difference between the below-freezing 
storage of fertility materials like sperm, 
which actually has a higher effectiveness in 
insemination when it has been cryogenically 
frozen for sixty days, and organ production 
materials, which want to be maintained at 
body temperature, 98.6 degrees Fahrenheit, 
means that each archive wall encompasses a 
field of different temperatures. This, coupled 
with the fact that active RMW treatment 
on-site means that plenty of excess high-
pressure steam is being coursed through the 
building provided a good way to structure hot 
and cold zones, and to place HVAC barriers 
throughout. 
Sample-based wall collections and their connected program-
matic needs. 
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SCENARIOS BEFORE DESIGN
The preceding scenarios were produced somewhere 
around the midterm. These poster designs were 
from July, when I was knee-deep in reading about 
biobanks and bio-tech but had absolutely no idea 
what to do next. I thought I might try to chan-
nel the kind of optimism and nationalism present in 
WPA-era poster designs, but ultimately spun my 
wheels for a few weeks while trying to figure out 
my priorities.
The images opposite are from the first weeks of 
the semester. I find it really useful to produce 
images of the conditions that I want to achieve in 
the project, well before I know details about where 
these moments might actually find themselves. 
This also helps to clarify ideas about program and 
transparency, and especially mood, which are hard 
to keep in the back of your mind while work-
ing on a plan. Most of all, for me, these types of 
exercises represent a much-needed break and an 
artifact of the design process that, regardless 
of how the design develops, can still be used in a 
presentation. 
What was most useful about the ones on the pre-
ceding pages was how I was able to finally marry 
some of my more conceptual ideas about the proj-
ect’s place in a new type of publicity/surveillance 
landscape, where issues of identity and the public 
were less scary but still part of the ‘big brother 
is watching’ atmosphere. 
RESEARCH
preserving humanity one drop at a time
CONTRIBUTE
BE A PART OF THE LIVING ARCHIVE
ILLUMINATING
THE MYSTERIES OF THE HUMAN GENOME
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DISEASE FERTILITY BLOOD + SALIVA
SAMPLE PROCESSING AND REGULATED 
AN EXAMPLE: 
MEDICAL WASTE TREATEMENT WALL
STRATEGY
Dividing the basic structure of the biobank 
down into six walls, each programmed for a 
different type of biospecien collection, meant 
that I needed to focus on access and trans-
parency issues in the walls themselves. It 
was important to me that both the public 
areas of the building, as well as the more 
private high-security laboratory areas, have 
access to the same samples, much as the 
public, after sufficient scrutiny, is able to 
access things in the Library of Congress. But 
at the same time, I wanted these walls to 
house vertical circulation and promote hori-
zontal circulation around and through them. 
The basic wall structure was arrived at by 
looking for a flexible system that might per-
mit an automated gantry to operate within 
it. The blocks that came to comprise these 
walls were scaled so that each wall could 
grow, and so that each wall could differ from 
the others according to its specific needs. 
In the diagram to the right, you can see 
how individual units build up to form these 
walls and how programs related to the spe-
cific contents of them might begin to cluster 
around this infrastructural hub. 
The wall’s structure permits breaks and 
openings while maintaining its automatic de-
livery function through the center, so pas-
sage through, beside, and around the archive 
becomes an integral part of working and 
visiting on both the private and the public 
floors. 
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DISEASE FERTILITY BLOOD + SALIVA
SAMPLE PROCESSING AND REGULATED 
AN EXAMPLE: 
MEDICAL WASTE TREATEMENT WALL
PIER WALK-THROUGH ARCHIVE ARCHIVE WITH OPENING STAIR TOP OF STAIR
ORGANS SAMPLE PROCESSING 
AND WASTE TREATMENT
WHOLE BODIES AND 
HISTORIC ANOMALIES
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OFFICES
PROCEDURES
TISSUE CULTURE
ARCHIVAL COLLECTION
STRUCTURE SKIN AND PIERS
RELATED RESTRICTED PROGRAMS
PATHOLOGY
MOLECULAR
HYBRID USE
75
Diagram showing one of six programmed archive walls and 
relationship to connected laboratory and research programs.
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tissue culture lab
public cafeteria
genealogical records database
pathology lab / MRI research
public gathering / varied circulation
Regulated Medical Waste steam sterilization treatment
steam wall travels up to tissue culture lab 
blood and saliva
organs
whole bodies and historic anomalies
disease
fertility
sample processing / archive acquisition
sterilized waste chute to landfill maintenance
inaccessible public view to private labs
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In addition to the discrete moments of one-
to-one visual connection - up and down 
around the labs, there are also larger mo-
ments within the building that provide ei-
ther large views into its workings - as one 
can see on the ground floor where medical 
waste is being processed immediately beside 
the public amphitheater, and where visitors 
in the upstairs genealogical research area or 
the cafeteria may observe live tissue culture 
or organ generation in action. 
In addition to choreographed peeks into 
the workings of the building, an alternating 
strategy of public and private floors is used 
to convey a sense that the entire building is 
public, if not actually unlocked or accessible. 
The interior strategy of oblique moves cre-
ating unexpected enclosure and partially ob-
structed views continues outside into the 
landscape, where a highly mediated back-
and-forth between the industrial necessities 
of processed medical waste landfilling and 
the more pastoral experience of a public park 
intermingle. In a strategy that is meant to 
welcome the public into a landscape that is 
obviously artificial, obviously made up of a 
new type of landfill or public artifact, these 
crystal-like boulders create curated views 
towards Upper New York Harbor while at 
the same time posing as a sort of funereal 
marker. 
The six programmed archive walls stand in a 
configuration that draws the public in from 
the nearby Liberty Science Center, the only 
public building in this area for miles, and be-
gin a conversation with the rest of the site. 
They bend to afford views from the upper 
floors of the biobank towards the Statue of 
Liberty, just south-east of the site, and they 
open and close to accommodate the loading 
docks necessary on the ground floor to bring 
access to the Blood, Fertility, Organs, and 
Sample Processing walls, all of which enjoy 
the site’s proximity to Newark International 
Airport just to the west, accessed by the 
New Jersey Turnpike. 
Public parking on site also follows the same 
strategy of accessing through and around 
major obstructions. The largest lot is ob-
scured below a synthetic groundscape be-
tween the science center and the biobank, 
allowing continuous views across the site. 
Coming up from the ferry terminal, the major 
promenade north/south on the site is large-
ly buffered from landfills on either side by 
great berms. To the east, and closer to the 
shore, a more meandering experience is im-
printed on the landscape, opening up pods for 
aquaculture support of the endangered New 
York Harbor north-east sturgeon, and pro-
viding discrete pockets of semi-wild nature, 
from which one can see lower Manhattan, as 
well as nearby Jersey City. 
The connection to ferry terminals also makes 
the entire site publicly active. Most visi-
tors would presumably arrive to the biobank 
via water from Lower Manhattan and walk 
through the manicured promenade of landfill 
berms. 
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View from the Liberty Science Center showing north biobank 
facade, productive landscape, and Statue of Liberty beyond. 
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1:1000
Plans of the main public and private spaces arrayed around 
the central roof break.
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Longitudinal and transverse sections through the biobank, 
showing RMW treatment facilities and laboratories above.
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DESIGN MODELS
At the final review, I found myself explaining the 
wall strategy by indicating on this model, below, 
how people would enter and exit it, and how it 
might be accessible for different types of material 
to come in and out. This was strictly a last-minute 
affair, but I was surprised how useful it was in 
terms of communicating what I was going for and 
what had perhaps not come across in the drawings. 
The building model to the right also helped review-
ers finally understand (I didn’t realize what was 
going on at the time) how the building was more 
or less cleaved in two, with two separate canopies 
enclosing two separate halves. 
85
86
NE-SW 1 | 1:500
NE-SW 2 | 1:500
NE-SW 3 | 1:500
PENULTIMATE REVIEW
With about three weeks to go, I presented this 
version of my project at the penultimate review. 
I was very much interested in the kind of sloping 
landscape of the outdoors entering into the build-
ing in a very blatant marker of space for public/
space for private. 
I’d been working with ideas about having the 
archive as this massive leaning tube through the 
building for a while, so in this case, the two spirals 
of public landscape and private laboratories circle 
around it. While I never said this out loud, at least 
in a review, in the back of my mind, I liked the idea 
that these intertwined sets of separate circula-
tion that connected only through the middle archive 
did kind of gesture towards the structure of DNA. 
Not to worry, though, this clunky box had too many 
things going on in it, and I ultimately revised it so 
that the archive was separated and more visible.
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Views towards Biobank from Ferry Landing dock, with land-
filled berms in between. 
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View from amphitheater through second floor pathology lab. 
Organ archive wall is visible on left. 
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View of public entry ramp sequence, with RMW treatment 
facilities beyond. 
(opposite) View through void above loading dock towards 
sample processing faciltiies. 
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View into tissue culture laboratory, with amphitheater 
steps visible through opening. 
Commercial road approach to the Biobank - how RMW might 
arrive at the site. 
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Public arrival to the cafeteria level. Laboratory peek-
through visible on left. 
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PROOF THAT I WAS THERE
Some images from the second review, from the mid-
term review, and from the final (thanks to Juliet, 
Ann, Tim, and Chai for these).
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There is no question that the successful 
cloning of Dolly the sheep, the Human 
Genome Project, and the beginning of DNA 
sequencing for preventative medicine have 
brought with them a new terrain of private 
and public health issues. Large-scale 
studies like the UK Biobank and small-scale 
sample collection for routine testing tap 
into a larger network of personal medical 
information being collected and recorded 
daily. There is increased concern about the 
privacy and security of genetic material once 
it has left its source. Might it be used in a 
new form of discrimination? Who might be 
able to access this information? Might it be 
used to produce clones or to fashion new 
types of people? Biomedical ethicists have no 
cohesive directive on this matter, other than 
to bring it to the light of legislators. This 
has, to some degree, been successful. The 
Genetic Privacy Act of 2008 was narrowly 
passed in both the House and the Senate, 
and finally ratified by GWH Bush in 2008. 
It aims to control public access to genetic 
information intended for research purposes, 
and to protect those who believe they have 
been victims of genetic discrimination. These 
efforts are well-intended, but it is a case of 
too little, too late.
INEVITABILITY
We have a medical establishment which 
thrives on the promise of confidentiality 
and reassurances of anonymity in cases of 
sample or specimen donation. This notion is 
nice, but patently false, as the Leader of 
the Personal Genome Project, and Director 
of the Computational Genetics Center at 
Harvard Medical School George M. Church, 
points out.1 His article in Nature was met 
in the scientific community with outrage 
1 Jeantine E. Lunshof, Ruth Chadwick, Daniel B. Vorhaus, 
and George M. Church, “From Genetic Privacy to Open 
Consent,” in section Perspectives,in Nature, Vol. 9, May 
2008, 406. 
Dolly the Sheepclone.
Genetic Privacy Legislation
the signing of H.R. 493, 
the Genetic Information Nondiscrimination Act of 2008
Wednesday, May 21, 2008 in the Oval Office
and horror, as he proceeded to break apart 
the long-held assurances of privacy in the 
medical establishment.2 He lists the ways in 
which information linking personal identity 
(name) with sample characteristics (data) 
can be accidentally released or hacked into 
during the course of a genetic study. The 
possibilities of failure are so great, he 
argues, that the expectation of privacy is 
actually what is at fault. It is better to 
come to grips with the permeability of so 
many firewalls and electronic barriers now 
than when your expectations have been 
disappointed. 
Church himself practices what he preaches. 
He maintains a website, http://arep.med.
harvard.edu/gmc/pers.html, where the data 
2 Daniel MacArthur, Genetic Future; How Genes Affect 
Your Future and the Future of Society (web blog). http://
scienceblogs.com/geneticfuture/2008/10/personal_ge-
nome_project_releas.php (accessed March 2 and 7, 2010).
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of his entire life, including commentary and 
signature, are available and download-able 
to the public, in an illustration of just how 
meaningless this data really is. We are not 
in fact defined by our mother’s maiden name 
or the curves in our signatures, or even in 
a resumé of our skills. Church’s Personal 
Genome Project aims to sequence small 
portions of the DNA of 100,000 volunteers 
to begin showing large-scale correlations 
between their appearances, backgrounds, 
affects, and dispositions, accounting, 
along the way, for differences in rearing 
environment and condition. This transparency 
affords an opportunity for action on a large 
public scale—accepting that information, 
medical especially, is trending towards total 
disclosure, doesn’t it make sense to legislate 
now for that condition, to prepare facilities 
for the collection of this data, and to support 
and regulate it centrally rather than through 
a dispersed network of privately and publicly 
funded research projects which may in fact 
interfere with one another?
Further, there is little hope of finding an 
international consensus on issues of genetic 
privacy and security. A special 2004 issue of 
the journal Ethics and Information Technology 
was devoted to the topic of private and 
public models for research and publishing of 
findings. A number of the field’s heavyweights 
share their views on best practices and the 
proposals for security on the international 
academic table right now. Property rights, 
for example, have been offered as a private 
partnership opportunity between research 
subjects and scientists, but this mode is 
assessed as artificially secure and actually 
hampering the flow of uncompromised 
research by introducing a commercial element 
into the mix.3 
CLONING
One objection to the total release of genetic 
information is the fear of cloning and the 
havoc it could wreak on society. The literature 
3 Richard A. Spinello, “Property Rights in Genetic 
Information,” in Ethics and Information Technology, Vol. 
6, 2004. 
seems divided between the patently optimistic 
and upbeat can-do attitude of those 
sequencing the human genome in an effort to 
prevent harmful diseases and those aware 
that not all scientists work for the same 
good. Medical theorist Hwa A. Lim offers 
simple observations in light of daunting 
problems: “The fact with human cloning is 
this: the technology is here and is being 
perfected,” he writes, partially withholding 
judgment on the topic. His views become 
more radical, however, when he observes 
that, “the genie is out of the bottle and 
the focus should be redirected: it is time for 
us to define civilization not by the things 
that the cloning technology makes possible, 
but by which of these possibilities we choose 
to undertake.”4 The advocating for a hybrid 
approach that blends philosophy into medicine 
and the identity of a society into the means 
of practice is remarkable, and an interesting 
template for issues of bioethics. If a problem 
is too vast and too active to solve, perhaps 
it can be used in a more reflective way, in 
a way that illuminates the conditions that 
created that very problem to start with. 
In his book, The Case Against Perfection, 
Michael J. Sandel offers increasingly dramatic 
parables of cloning and genetic therapy in order 
to tease out the reader’s own prejudices.5 
He chooses topics which are “already on the 
horizon,” to effectively explain how complex 
4 Hwa A. Lim. Multiplicity Yours: Cloning, Stem Cell Re-
search, and Regenerative Medicine. (New Jersey: World 
Scientific, 2006), 340.
5 Michael J. Sandel. The Case Against Perfection; Ethics 
in the Age of Genetic Engineering. (Cambridge, MA: The 
Belknap Press of Harvard University Press, 2007), 10. 
Library of Congress
Washington, DC: 1800
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the ethics issues surrounding genetics can 
be. He writes of “muscle enhancement, 
memory enhancement, height enhancement, 
and sex selection. In each case, what 
began as an attempt to treat a disease or 
prevent a genetic disorder now beckons as 
an instrument of improvement and consumer 
choice.”6 The trajectory from unobjectionable 
scientific research to consumer product is 
already underway. There is no way to draw a 
clear line between therapeutic and necessary 
medical procedures and the ones elected to, 
which cause such ethical dilemmas. Consider 
the awkward and unclear situations in which 
MicroSort, a sperm-sorting procedure which 
produces highly reliable gender selection 
is used. This technology was developed by 
the U.S. Department of Agriculture for the 
breeding of cattle; while the same effect may 
be desired in both cases, the selection of sex 
for a human being is seen as significantly more 
grave, and an excessive use of the machine. 
Regardless of the reason for which couples 
may want to select the sex of their child, it 
is ethically difficult for any government to 
ban this process while they continue to use 
the technology, albeit on different subjects 
and towards different ends. Perhaps if 
there were no grey area, if there were no 
sticky or unclear situations, legislation might 
stand a chance. As it lies now, the march 
toward inevitable ‘progress,’ or at least the 
increasing use of available technologies for 
genetic selection and manipulation, will only 
increase in speed. 
6 Sandel, 10.  
The Memex
Vannevar Bush, 1939
ARCHIVE 
The history of the archive is fraught. The 
archive-as-research-library model that we 
know now has not long been in service. The 
first libraries set out with grand, but not 
public, intentions; The Ancient Library of 
Alexandria, founded circa 295 BCE, attempted 
to amass the world’s largest collection 
of knowledge, and to make these scrolls 
available to suitable scholars and writers, 
but not the general public.7 The articles in the 
Alexandria collection were collected through 
copying and often through force. The concept 
of the “Universal Library,” which Alexandria 
presented did not disappear as quickly as 
Alexandria itself, as Sascha Hastings points 
out – the United States Library of Congress 
has  ambitions on the scale of a universal 
library, in that it attempts to make a record 
of all published books in the United States, 
classifying them into subject headings and 
intentionally affecting the way that books 
are read, not just organized. Similar to 
Alexandria, the Library of Congress has a 
very limited availability for interaction with its 
materials. Only researchers who have applied 
for permission with samples of their work 
and descriptions of their research projects 
may enter into the designated reading areas. 
A more conceptual archive, or one that 
does not physically involve the collection 
of information in one centralized location, is 
Conrad Gesner’s 1545 Bibliotheca Universalis.8 
This archive is actually a bibliography, a list 
of the world’s known books, with the idea 
first of letting other collectors or librarians 
strategically build their collections, and 
second, “if Christendom collapsed, and all 
libraries were destroyed, a single copy of the 
Bibliotheca Universalis would allow survivors 
to realize what they had lost, which might at 
7 Sascha Hastings and Esther E. Shipman, eds., Logoto-
pia; The Library in Architecture, Art, and the Imagina-
tion (Montréal, Canada: Cambridge Galleries Design at 
Riverside), 2008, 12. 
8 Robert Jan Van Pelt, “The Universal Library,” in Sascha 
Hastings and Esther E. Shipman, eds., Logotopia; The Li-
brary in Architecture, Art, and the Imagination (Montréal, 
Canada: Cambridge Galleries Design at Riverside), 2008, 
16. 
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Identification Anthropométrique
Alphonse Bertillon, 1893
(in Allan Sekula, The Body and the Archive)
least trigger a desire to recover it.”9 This type 
of meta-collection, the recipe for a library, 
or the listing of what exists, describes a 
drive similar to that of the Universal Library, 
but different in one significant way – it does 
not contain any unique information on its own, 
only references. In this way, this document 
which could be so valued in the distributing of 
information about library building, is actually 
devoid of use. As you will see in the example 
of Vannevar Bush and his Memex, below, at 
a certain point, the real issues at stake in 
a library or collection are not the artifacts 
themselves (though sometimes large objects 
present problems of their own), but rather 
the method which with they are retrieved and 
referenced. Without a record of its existence 
and a way to access it, a book may as well 
not exist at all. 
The act of saving and organizing information 
is not inherently critical. Cornelia Vismann 
points out that, “The dogma of complete 
documentation and the tendency towards 
more and more detailed reports led to the 
well-known proliferation of files. Archivists 
are not, after all c(h)ancellors. Even when 
the storage weight became unbearable and 
the data became outdated before it could 
be used, archivists were not even trained 
9 Jan Van Pelt, 16. 
as file-eliminators. The only way to liberate 
the world from the crushing weight of files 
became their material destruction. A virtual 
third institution, after chancery and archive, 
emerged: that of wastepaper.”10 And so with 
the library comes a kind of anti-library, 
a place where all things that may or may 
not have been destroyed go to potentially 
wreak havoc and cause scandal. Even when 
information exists only in a single hard-copy 
format and that paper is shredded, Vismann 
further points out that even shredded 
paper can be digitally scanned and rebuilt 
according to its tear patterns. To archive is 
to acknowledge the breaches that plague the 
archive. To archive is to risk the existence 
of the archived material itself. 
In a similar light, the problem of organizing 
archived information is addressed head-on in 
a pair of articles written by Vannevar Bush, 
vice-president and dean of engineering at M.I.T. 
from 1932 to 1938, in the Atlantic Monthly and 
in his own book, Science is Not Enough (1945 
and 1967).11 Bush doesn’t focus on the dangers 
of lost (or not lost-enough) information, as 
Vismann does. Rather, he fixates on the 
10 Cornelia Vismann, “Out of File, Out of Mind,” in Wendy 
Hui Kyong Chun and Thomas Keenan, eds., New Media, 
Old Media (New York: Routledge), 2006. 100. 
11 Vannevar Bush, “Memex Revisited,” in Wendy Hui 
Kyong Chun and Thomas Keenan, eds., New Media, Old 
Media. (New York: Routledge,) 2006, 86. 
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difficulties of storing the increasing amount 
of information being generated. He proposes 
a new device to store information, which 
works essentially as a desk console which 
stores and retrieves constantly updated 
microfilm. As the rate of communication and 
the technologies of recording became more 
advanced, he suggested, the most important 
piece of information would be the thread 
which connected items of interest, both for 
the individual user of his own memex, and 
for the individual subscribing to collections 
of links  and trails that his friends found 
useful. This networking of information in a 
constant web is familiar as a metaphor of 
the internet. The archive is a changing beast, 
but the need to establish clear, legible paths 
through it is not. 
Finally, on the topic of the archive, Allan 
Sekula’s Foucauldian reading of photographic 
archives in The Body and the Archive can 
serve as a type of warning of the dangers 
inherent in the confluence of body and drive 
to document it.12 Sekula describes numerous 
attempts to classify the body, especially 
using photographic means. Since the advent 
of photography, he points out, there have 
been attempts to divine information from the 
standardized reading of physiognomies and 
physical typologies of facial features. He 
describes in particular the repressive forces 
at work in the collection of images as mug 
shots used for the identification of criminals, 
but explains, “the problems with prior 
attempts at criminal identification were many. 
The early promise of photography had faded 
12 Allan Sekula, “The Body and the Archive,” in October, 
Vol. 39 (Winter, 1986), 16.
Svalbard Seed Bank
in the face of a massive and chaotic archive 
of images. The problem of classification was 
paramount.”13 Sekula discusses the Bertillon 
system of classification, a taxonometric 
method of determining the relative criminal 
predisposition of a suspect. Until the 
advent of the fingerprint and the relatively 
small-scale storage and comparison 
problem that it presented, the Bertillon 
method of identification produced reams of 
measurements of the sides of heads, the 
angles in noses, and the length of eyelids. 
Finally, as the fingerprint reduces all of 
this measurement and complex identification 
into one small surface, he writes that, “it 
became evident that the body did not have 
to be ‘circumscribed’ in order to be identified. 
Rather, the key to identity could be found 
in the merest trace of the body’s tactile 
presence in the world.”14 The moment of 
identification through the fingerprint is the 
beginning of the end for a long-held flimsy 
concept of protectable and valuable individual 
identity. 
The problem of organization is inherent in the 
collecting of things. The differences between 
the Library of Congress Catalog system, now 
widely preferred, and the Dewey Decimal 
System are hardly noticeable when you 
consider the informal ways that information 
is organized – the trend for organizing a 
bookcase or a bookstore according to the 
color of book covers, for example. The archive 
of biological material must materialize in 
architecture its own system of organization, 
otherwise it stands no chance of continued 
13 Sekula, 26. 
14 Sekula, 34. 
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viability. To aim for an archive that archives 
itself is, I think, an important goal when 
considering an institution with a potentially 
long lifetime. Whether it is in considering 
the information that is lost (or found, in 
light of an argument for total informational 
transparency with genetic material), or in the 
creation of a new system of data recall and 
sharing, this archive of bio-material must 
integrate within itself a system by which its 
retrieval is ensured. 
SEED BANK
The seed bank holds an interesting precedent 
for the saving of biological material, but one 
that has distinctly different aims than a 
biobank. The Svalbard Seed Bank, and many 
other local or specialized seed banks, promote 
diversity in the crop population, a possible 
antidote to the drive towards monoculture 
and large food corporations’ drive towards 
engineered plants. By saving samples of 
different crop varietals, the argument goes, 
we guard ourselves against possible food 
emergencies and the degradation of our food 
supply by pest infestation and progressive 
mutation. A slightly radical wing of the seed-
saving movement, a group called “Primal 
Seeds,” uses simple statistics to drive home 
the need for diversity. “Filipino farmers once 
grew thousands of kinds of rice. Today only 
two varieties account for 98% of the area 
sown. Mexico has lost an estimated 80% of 
its varieties of maize. Of 8000 traditional rice 
varieties being grown in China in 1949, only 50 
remained in 1971.”15 
The Svalbard Seed Bank in Norway is buried 
deep into the side of a tall mountain, far 
enough north that perma-frost effectively 
maintains a consistent cold temperature.16 
While the facility itself is cooled beyond what 
the surrounding environment can maintain, 
any loss of power or dramatic climactic 
shift would be mitigated significantly by 
15 “Primal Seeds,” organizational website, http://www.
primalseeds.org/ (accessed February 27 and March 6, 
2010). 
16 Svalbard Seed Bank, official program website, http://
www.regjeringen.no/en/dep/lmd/campain/svalbard-global-
seed-vault.html?id=462220 (accessed February 28 and 
March 7, 2010).
Cryogenic Storage
California Cryobank, Los Angeles
the long period over which the area would 
defrost. Further, the site is placed at a high 
enough elevation that sea-level rise is not 
an immediate (or even doomsday-immediate) 
concern. This example is instructive not only 
because of the effort given to securing the 
facility temperature-wise, but because of the 
administration of the project. The Svalbard 
Seed Bank is not an active facility in the 
sense that researchers are a constant 
presence. The ‘vault’ is opened twice a year 
to add additional seed packets. Further, the 
seeds are never touched by administrators 
of the seed bank – it is essentially a very 
large and expensive safety-deposit box for 
duplicates of seeds already being stored in 
existing seed banks around the world. This 
meta-seed-bank has an important role as a 
secure institution and insurance plan, but it is 
not active in any real sense. Seeds, as well, 
have a limited lifespan in storage, and must 
be germinated and harvested periodically to 
maintain their fertility. In this model, seed 
banks participating in the Svalbard seed 
program must continually renew their stored 
stock. 
As a precedent for an active biobank, the 
Svalbard example can illustrate an extreme 
security situation, but definitely not the 
type of facility that would interface with 
the public in any real way. Security and 
storing for posterity can be read in different 
lights, since the secure-but-remote model 
becomes a type of time capsule rather than 
civic institution. Other examples of extreme 
security measures can be seen in digital 
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storage warehouses like facilities maintained 
by Iron Mountain, an international publicly-
traded company that specializes in secure 
storage. As their company profile explains, 
“we currently safeguard and provide access 
to more than 425 million cubic feet of 
paper records, 10 billion emails, 65 million 
computer backup tapes, 2.5 million PCs and 
20,000 servers, and the list is exponentially 
growing.”17 Iron Mountain also builds literally 
into the side of a mountain in order to store 
server warehouses and guard against the 
threat of natural disasters and security 
breaches. The ‘mountain’ typology is one way 
to approach security, but one that I don’t 
believe is sustainable (not just in the fact 
that whole mountains are being hollowed out 
in the service of industry). An important 
goal is the discovery of a public architecture 
which can at once be a visual and conceptual 
presence in the life of a society. Hiding, 
even in plain sight, positions a collection 
negatively, as constantly on the defensive. 
A new type of biobank would openly declare 
its intentions and contents, welcoming the 
public to engage with the products of 
research without unduly posing a threat to 
the collection itself. Further, there can be 
little objection to the need to store seeds 
or digital information. The argument for the 
storage of human genetic material is slightly 
stickier. While it employs the same research 
logic as a seed bank, and employs the same 
security conventions of a data warehouse, 
the fact that human identity markers are 
stored positions the project in a decidedly 
different moral and ethical territory. 
All sorts of biobanks are already in 
operation in the United States. Since the 
early 1970s, in-vitro fertilization therapy, 
or IVF, has been used successfully to help 
hundreds of thousands of couples reproduce. 
At the outset of the use of this technology, 
debates similar to those currently 
surrounding cloning took place. The public 
raised questions of morality and ethicality 
17 Iron Mountain, company profile on organizational 
website. http://www.ironmountain.com/company/about-us.
html (accessed March 7, 2010).
in ‘playing G-d’ with reproductive science. 
“The disparate reticence crystallized in 1974 
when the Congress forbade the HEW to 
fund any research on human fetuses, except 
that which might improve the survival rate 
of fetuses.”18 Not being able to certify that 
research was directly in aid of prolonging 
the lives of fetuses, researchers found 
funding from other sources. They “received 
support from private philanthropies such 
as the Ford Foundation and the Rockefeller 
Foundation, the Population Council, the 
Planned Parenthood Federation, and the 
Carnegie Corporation. They also had grants. . 
. . Congress’  action forced IVF researchers 
to rely solely on private sources, or to turn 
their IVF efforts into lucrative enterprises 
and the IVF community responded.19 
This movement of medical research from 
the public to the private domain meant (and 
continues to mean today) that only those 
with sufficient resources (and IVF therapy 
can become astronomical) have access to 
this technology. Lim sees this break from 
institutionalized national research arms as 
a positive, or at least progressive, move. 
“As it turned out, the high demand for IVF 
services provided a ready flow of cash 
to fund the research: the segment of the 
American population who was desperate 
and could afford not only were willing to 
allow physicians to use them as experimental 
subjects, but also to foot the bill for IVF. 
These private sector dollars eliminated the 
need for future federal involvement and gave 
researchers far more latitude than they 
would otherwise have had they relied on 
federal funding.”20 This movement of course 
means that great leaps have been taken in 
IVF techniques and results in the past thirty 
years, but it also means that there is a 
significant class divide among those who can 
and those who cannot afford this therapy for 
themselves. By and large, health insurance 
does not cover fertility treatment, except in 
cases of danger to the health of the mother. 
The movement to a centralized and public 
18 Lim, 342. 
19 Lim, 342. 
20 Lim, 342. 
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biobank would make genetic therapy available 
across the board, equalizing the ‘playing 
field’ of therapeutic opportunity, and making 
private research facilities accountable for 
their activities. 
IVF relies on the availability of material 
to fertilize. While many couples implant 
embryos fertilized from their own material, 
still others, for a variety of reasons 
(lesbian couples, infertility, low motility, 
etc.) require the resources of donated or 
purchased sperm or eggs. California Cryobank 
is one of the most successful warehouses of 
sperm and ova in the country, and markets 
itself almost as an amazon.com of fertility 
material.21 Customers can look through 
catalogs of sperm donors, selecting for race, 
ethnicity, height, eye color, talents, among 
other characteristics. A particular innovation 
at the California Cryobank is additional (and 
more expensive) background services on its 
donors for potential customers. Prospective 
parents can purchase baby photos of their 
donor, extensive psychological temperament 
summaries, and even the right to contact 
the donor in shift from the traditional 
anonymous donor schema. Perhaps because 
of the unique privately-funded structure 
that IVF has grown up around its discipline, 
the subtle nods towards eugenics largely 
go unmonitored in this selection process. 
As Dr. Lim asks, “what, after all, is the 
moral difference between designing children 
according to an explicit eugenic purpose and 
designing children according to the dictates 
of the market? Whether the aim is to 
improve humanity’s ‘germ plasm’ or to cater 
to consumer preferences, both practices are 
eugenic insofar as both make children into 
products of deliberate design.”22 What at 
first appeared to be a very fine line between 
genetic therapy and morally reprehensible 
culling of the population now appears to be 
nonexistent. It is impossible to distinguish 
between selection based on genetic identity 
and the type of categorizing and generalizing 
that has historically grown up around 
21 California Cryobank, organizational website, http://
www.cryobank.com/ (accessed March 1, 2010). 
22 Sandel, 75.
eugenics. 
Finally, eggs and sperm are not the only 
products that California Cryobank markets: 
they also offer storage services for your 
own material, as well as storage for umbilical 
cords immediately after birth. These elements 
of the business model are important because 
they begin to stretch over the boundary of 
direct help to fertility challenged couples 
and into a long-term storage situation with 
inherent moral difficulties. During IVF therapy, 
multiple eggs are fertilized in an attempt to 
increase the odds of successful pregnancy. 
Typically, one round of treatment will result 
in five or six implantable embryos.23 For the 
health of the mother and for the safety 
of the nascent children, if multiple embryos 
successfully implant themselves, sometimes a 
procedure of selective abortion takes place, 
removing the least viable embryos. Additionally, 
cord blood storage is encouraged as a way 
of creating health security for the born child 
– the frozen umbilical cord is a source of 
identical stem cells which could potentially 
be used in genetic therapy in the future. 
With both of these cryogenically frozen and 
stored samples, a problem arises when the 
fertility treatment has been successful or 
the baby has been determined fully healthy. 
Having saved this large sample of genetic 
material and invested so much financial and 
moral energy into the process, how does one 
ethically dispose of material, or rather, what 
does a couple do when they are done? 
Michael Sandel, a medical ethicist and theorist, 
recounts his engagement of this issue as 
part of a medical ethics debate. 
I recently participated in a stem cell debate 
with a proponent of the view that a blastocyst 
is morally equivalent to a baby. After our 
exchange, a member of the audience related 
a personal experience. He and his wife had 
successfully conceived three children by 
means of in vitro fertilization. They had no 
desire for more children, and yet three viable 
embryos remained. What, he asked, should he 
23 In Vitro Fertilization, Wikipedia the free encyclopedia. 
http://en.wikipedia.org/wiki/In_vitro_fertilisation (ac-
cessed March 5). 
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and his wife do with these excess embryos?
“My right-to-life interlocutor replied that 
it would be wrong to exploit the embryos 
by using them (and destroying them) for 
stem cell research. Assuming no one was 
available to adopt them, the only thing to do 
was to let them die with dignity. Given the 
assumption that these embryos were morally 
equivalent to children, I could not quarrel 
with his conclusion. . . . 
“What I found puzzling about this answer 
was not his unwillingness to sanction the 
use of the embryos for research, but his 
reluctance to articulate the full implications 
of his position. If those embryos really 
are young human beings, then the honest 
answer would be to tell the questioner that 
what he and his wife did in creating and 
discarding those embryos was nothing less 
than creating three surplus siblings of their 
children, and then abandoning the unwanted 
siblings to die by exposure on a mountainside 
(or in a freezer).24
This example makes clear that very little 
is clear in terms of moral and ethical 
governance of fertility treatment. Further, 
there is very little in the way of current 
regulation on private enterprises like this 
one, and to allow a system which provides 
basic biological needs for desperate couples 
of only a single class seems itself morally 
reprehensible. 
POST-HUMAN
Posthumanism is a buzz-word in both genetic 
theory research and in cultural critique. 
Popular models or science-fictional fantasies 
of posthumanism seem to make up the largest 
influence on the public in terms of how a 
future race of quasi-’natural’, genetically 
manipulated or hybridized humans might live. 
In his introduction to the special issue of 
Cultural Critique  entitled “Posthumanism,” 
Bart Simon points out the subtleties of 
changing biology, and how many scenarios are 
already present and operational.25 While The 
24 Sandel, 123.
25 Bart Simon, “Introduction: Toward a Critique of Post-
human Futures,” in Cultural Critique, No. 53, Posthuman-
ism (Winter, 2003), 6.
Matrix may present one model of posthuman 
cyborg-esque alternate-plane operation, the 
reality now is that most of our food has 
been genetically modified, and most crops 
are filtered through the massive corporate 
machine of Monsanto. To find a single point 
around which to draw the line between natural 
human and posthuman seems itself artificial 
and does not sufficiently acknowledge the 
trajectory that we have been on for the past 
hundred years. To theorize the posthuman is 
useful perhaps in a conceptual or theoretical 
light, but not ultimately applicable to the 
years of research already underway. 
SITE and PROPOSAL
I propose a biobank as a national institution, a 
centralized location of data and resources of 
physical samples. These materials are already 
being collected, with little real promise for 
anonymity or security, and I propose to make 
this process transparent, to give a public 
face to a potentially scary, but ultimately 
inevitable, reality as we progress as a 
society. Cloning, fertility, storage, archiving, 
and the philosophical effects on identity will 
all be important branches of this project, 
but not the project itself. I intend to design 
a building that centralizes research and 
storage with a monumental aspect, with the 
weight of an sanctioned institution. 
While many seed banks or architectural 
precedent typologies resort to bunker-type 
security measures in order to protect their 
contents, I propose to act in opposition 
to this trend. I don’t believe that an open 
and difficult dialogue is possible without 
the symbolic content of debate physically 
present. For this reason, my biobank will be 
sited and will act more like the California 
Cryobank than the Svalbard Seed Bank. It will 
be situated at a central transportation and 
shipping hub in the continental United States. 
An interesting opportunity is presented at 
the Louisville, KY site of the UPS WorldPort, 
the largest (and growing) single shipping and 
sorting station of its kind in the world. Most 
UPS packages are shipped directly to this 
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facility to be recategorized and shipped out 
to their destinations. The WorldPort is larger 
than the commercial airport on whose grounds 
it is located, and ships hundreds of thousands 
of packages all over the United States daily. 
A highly specialized process of labeling and 
sorting allows for packages to be touched 
only twice (and briefly) during their stay 
at the WorldPort. A number of businesses 
involved in large-scale delivery systems 
have already located themselves near the 
UPS hub to facilitate a symbiotic relationship 
between the transportational mechanism and 
the product. Clearwater Seafoods, profiled in 
John McPhee’s resume of unusual industrial 
practices, has done just that in situating 
its lobster-resting facility almost directly 
adjacent to the UPS WorldPort.26 
CONCLUSION
It is clear that very little is clear or 
straightforward in the new world of genetic 
engineering. There is much good to be done 
and therapies to be developed based on the 
sequencing of the human genome, but there 
is also much evil. My thesis accepts both 
of these possibilities and rejects the notion 
that evil can be avoided. The only ethical and 
effective solution to the problem of genetic 
information security and manipulation is a 
movement towards complete transparency. 
This trend can be observed in the evolution 
of internet information security, and it is 
unstoppable. If any type of electronic data is 
to be recorded in conjunction with our genetic 
material, and it is, every single time you get 
a blood test at Quest Diagnostics, every 
time you give blood in a Red Cross donation 
truck, and every time you get fitted for a 
new pair of glasses, then why not share 
all of it, why not take on an attitude of 
complete disclosure in order to better own 
what cannot be replicated. 
The BioBank is not a new concept—it is 
not programmatically revolutionary or 
radically different from facilities that are 
in operation now, except for its purpose, its 
26 John McPhee, Uncommon Carriers (New York: Farrar, 
Straus and Giroux, 2006), 164. 
publicity, and its place in civic life. The Bio-
Bank centralizes data that already exists 
in pernicious and hidden ways, making it 
transparent and accessible. Because the Bio-
Bank is centralized, it can be regulated, it can 
be watched over and maintained in acceptable 
conditions. An analogy between biobanking 
and monetary banking might compare an 
online bill-paying service (as a consolidation 
of the active part of saving and retrieving 
money) to the biobank. 
It is better to give up the illusion of privacy 
than to be unpleasantly surprised when it 
inevitably falters. 
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